0001171843-20-003601.txt : 20200511 0001171843-20-003601.hdr.sgml : 20200511 20200511172316 ACCESSION NUMBER: 0001171843-20-003601 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200511 DATE AS OF CHANGE: 20200511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XBiotech Inc. CENTRAL INDEX KEY: 0001626878 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37347 FILM NUMBER: 20866121 BUSINESS ADDRESS: STREET 1: 8201 E. RIVERSIDE DRIVE STREET 2: BUILDING 4, SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78744 BUSINESS PHONE: 512-386-2930 MAIL ADDRESS: STREET 1: 8201 E. RIVERSIDE DRIVE STREET 2: BUILDING 4, SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78744 10-Q 1 f10q_051120p.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

ý	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2020

¨	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission File Number 001-37437

XBIOTECH INC.

(Exact name of registrant as specified in charter)

British Columbia, Canada		__
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

5217 Winnebago Ln, Austin, TX 78744

(Address of principal executive offices)(Zip Code)

Telephone Number (512) 386-2900

(Registrant’s telephone number, including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	XBIT	NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ý No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	ý
Non-accelerated filer	¨	Smaller reporting company	ý
		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No ý

As of May 11, 2020, there were 28,852,927 shares of the Registrant's common stock issued and outstanding.

XBIOTECH INC.

THREE MONTHS ENDED MARCH 31, 2020

INDEX

PART I—FINANCIAL INFORMATION
Item 1.	Consolidated Financial Statements
	Consolidated Balance Sheets as of March 31, 2020 (unaudited) and December 31, 2019	6
	Consolidated Statements of Operations for the Three Months Ended March 31, 2020 (unaudited) and 2019(unaudited)	7
	Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2020 (unaudited) and 2019 (unaudited)	8
	Consolidated Statements of Shareholders’ Equity for the Three Months Ended March 31, 2020 and 2019 (unaudited)	9
	Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 (unaudited) and 2019 (unaudited)	10
	Notes to Consolidated Financial Statements (unaudited)	11
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27
Item 4.	Controls and Procedures	27
PART II—OTHER INFORMATION
Item 1.	Risk Factors	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29
Item 3.	Defaults Upon Senior Securities	29
Item 4.	Mine Safety Disclosures	29
Item 5.	Other Information	29
Item 6.	Exhibits	30

SIGNATURES

CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “would,” “could,” “expects,” “plans,” “contemplate,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “intend” or “continue” or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These forward-looking statements include, but are not limited to statements about:

potential impacts due to the coronavirus pandemic such as delays, interruptions or other adverse effects to clinical trials, delays in manufacturing and supply chain interruptions, and the overall impact of the coronavirus pandemic on our business, financial condition and results of operations;

our ability to obtain regulatory approval to market and sell our product candidates in the United States, Europe and elsewhere;

the initiation, timing, cost, progress and success of our research and development programs, preclinical studies and clinical trials for our product candidates;

our ability to advance product candidates into, and successfully complete, clinical trials;

our ability to successfully commercialize the sale of our product candidates in the United States, Europe and elsewhere;

our ability to recruit sufficient numbers of patients for our future clinical trials for our pharmaceutical products;

our ability to meet our drug manufacturing and clinical trial management obligations under our contractual arrangements with Janssen;

our ability to achieve profitability;

our ability to obtain funding for our operations, including research funding;

our ability to identify additional new products using our True Human™ antibody discovery platform;

the implementation of our business model and strategic plans;

our ability to develop and commercialize product candidates for orphan and niche indications independently;

our commercialization, marketing and manufacturing capabilities and strategy;

our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;

our expectations regarding federal, state and foreign regulatory requirements;

the therapeutic benefits, effectiveness and safety of our product candidates;

the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our products and product candidates;

the rate and degree of market acceptance and clinical utility of our future products, if any;

the timing of and our collaborators’ ability to obtain and maintain regulatory approvals for our product candidates;

our expectations regarding market risk, including interest rate changes, foreign currency fluctuations and regional or global economic impacts caused by public health threats, such as the outbreak of coronavirus or other infectious diseases;

our belief in the sufficiency of our cash flows to meet our needs for at least the next 12 to 24 months;

our ability to engage and retain the employees required to grow our business;

our future financial performance and projected expenditures;

developments relating to our competitors and our industry, including the success of competing therapies that are or become available; and

estimates of our expenses, future revenue, capital requirements and our needs for additional financing.

All forward looking statements in this Quarterly Report on Form 10-Q involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those under the heading “Risk Factors” included in our annual report for the year ended December 31, 2019 filed with the SEC on March 16, 2020, and under the heading “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business, and the markets for certain medical conditions, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.

XBiotech Inc.

Consolidated Balance Sheets

(in thousands, except share data)

	March 31, 2020			December 31, 2019
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	241,540		$	714,594
Accounts receivable		9,681			-
Deferred cost of goods sold		1,703			-
Income tax receivable		3,793			-
Prepaid expenses and other current assets		1,179			1,669
Total current assets		257,896			716,263
Property and equipment, net		25,034			25,171
Escrow receivable		75,000			75,000
Deferred tax asset		443			443
Total assets	$	358,373		$	816,877

Liabilities and shareholders’ equity
Current liabilities:
Accounts payable	$	5,649		$	2,149
Accrued expenses		1,371			4,180
Contract Liabilities		-			4,500
Deferred revenue		1,500			-
Income taxes payable		1,715			49,361
Total current liabilities		10,235			60,190
Long-term liabilities:
Deferred rent		-			-
Income tax payable - non-current		1,056			1,056
Total liabilities		11,291			61,246

Shareholders’ equity:
Preferred stock, no par value, unlimited shares authorized, no shares outstanding		-			-
Common stock, no par value, unlimited shares authorized, 28,852,927 and 41,519,633 shares outstanding at March 31, 2020 and December 31, 2019, respectively		242,942			324,808
Accumulated other comprehensive loss		(16	)		(106	)
Retained earnings		104,156			430,929
Total shareholders’ equity		347,082			755,631

Total liabilities and shareholders’ equity	$	358,373		$	816,877

See accompanying notes.

XBiotech Inc.

Consolidated Statements of Operations

(in thousands, except share and per share data)

	Three Month Ended March 31,
	2020			2019
	(unaudited)			(unaudited)
Revenue
Manufacturing revenue	$	3,000		$	-
Clinical trial service revenue		9,681			-
Total revenue		12,681			-
Cost of goods sold
Manufacturing cost		2,166			-
Clinical trial cost		7,508			-
Total cost of goods sold		9,674			-
Gross margin		3,007			-

Operating expenses:
Research and development		1,155			4,527
General and administrative		4,023			1,278
Total operating expenses		5,178			5,805
Loss from operations		(2,171	)		(5,805	)

Other income (loss):
Interest income		1,898			78
Other income		-			9
Foreign exchange loss		(93	)		(146	)
Total other income (loss)		1,805			(59	)
Loss before income taxes		(366	)		(5,864	)
Provision for income taxes		(352	)		-
Net loss	$	(14	)	$	(5,864	)
Net loss per share—basic and diluted	$	(0.00	)	$	(0.16	)
Shares used to compute basic net loss per share		36,169,493			35,977,422

See accompanying notes.

XBiotech Inc.

Consolidated Statements of Comprehensive Loss

(in thousands)

	Three Months Ended March 31,
	2020			2019
	(unaudited)			(unaudited)

Net loss	$	(14	)	$	(5,864	)
Foreign currency translation adjustment		90			138
Comprehensive loss	$	(76	)	$	(5,726	)

See accompanying notes.

XBiotech Inc.

Consolidated Statements of Shareholders' Equity

(in thousands)

	Number of Shares			Common Stock Amount			Accumula-ted Other Compre-hensive Income (Loss)			Accumulated Deficit (Equity)			Total
Balance at December 31, 2019		41,519			324,808			(106	)		430,929		$	755,631
Net loss		-			-			-			(14	)		(14	)
Tender offer buyback		(14,000	)		(93,240	)		-			(326,760	)		(420,000	)
Foreign currency translation adjustment		-			-			90			-			90
Issuance of common stock under stock option plan		1,334			7,918			-			-			7,918
Share-based compensation expense		-			3,456			-			-			3,456
Balance at March 31, 2020		28,853		$	242,942		$	(16	)	$	104,155		$	347,082

	Number of Shares		Common Stock Amount			Accumula-ted Other Compre-hensive Income (Loss)			Accumulated Deficit			Total
Balance at December 31, 2018		35,900	$	279,353		$	(255	)	$	(237,700	)	$	41,398
Net loss		-		-			-			(5,864	)		(5,864	)
Foreign currency translation adjustment		-		-			138			-			138
Issuance of common stock under stock option plan		190		643			-			-			643
Stock subscription receivable		-		(102	)		-			-			(102	)
Collection of stock subscription receivable		-		200			-			-			200
Share-based compensation expense		-		570			-			-			570
Balance at March 31, 2019		36,090	$	280,664		$	(117	)	$	(243,564	)	$	36,983

See accompanying notes.

XBiotech Inc.

Consolidated Statements of Cash Flows

(in thousands)

	Three Months Ended March 31,
	2020			2019
	(unaudited)			(unaudited)
Operating activities
Net loss	$	(14	)	$	(5,864	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		558			602
Share-based compensation expense		3,456			570
Account receivable		(9,681	)		-
Deferred cost of goods sold		(1,703	)		-
Income tax receivable		(3,793	)		-
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		489			230
Accounts payable		3,470			99
Accrued expenses		(2,815	)		(311	)
Deferred revenue		(3,000	)		-
Deferred rent		-			(3	)
Tax payable		(47,640	)		-
Net cash used in operating activities		(60,673	)		(4,677	)

Investing activities
Purchase of property and equipment		(389	)		(6	)
Net cash used in investing activities		(389	)		(6	)

Financing activities
Share repurchases of common stock and warrants, net		(420,000	)		541
Issuance of common stock under stock option plan		7,918			200
Net cash provided by (used in) financing activities		(412,082	)		741
Effect of foreign exchange rate on cash and cash equivalents		90			138

Net change in cash and cash equivalents		(473,054	)		(3,804	)
Cash and cash equivalents, beginning of period		714,594			15,823
Cash and cash equivalents, end of period	$	241,540		$	12,019

Supplemental Information:
Accrued purchases of property and equipment		32			109
Subscription receivable		-			102

See accompanying notes.

XBiotech Inc.

Notes to Consolidated Financial Statements (Unaudited)

Organization

XBiotech Inc. (XBiotech or the Company) was incorporated in Canada on March 22, 2005. XBiotech USA, Inc., a wholly-owned subsidiary of the Company, was incorporated in Delaware, United States in November 2007. XBiotech Switzerland AG, a wholly-owned subsidiary of the Company, was incorporated in Zug, Switzerland in August 2010. XBiotech Japan K.K., a wholly-owned subsidiary of the Company, was incorporated in Tokyo, Japan in March 2013. XBiotech Germany GmbH, a wholly-owned subsidiary of the Company, was incorporated in Germany in January 2014. The Company’s headquarters are located in Austin, Texas.

Since its inception, XBiotech has focused on advancing technology to rapidly identify and clone antibodies from individuals that have resistance to disease. At the heart of the Company is a proprietary technical knowhow to translate natural human immunity into therapeutic product candidates.

In 2005, the Company began to develop a new framework for commercial manufacturing, using technology that required less capital, fewer operators and provided greater flexibility than standard industry practices.

With the manufacturing capability to produce its True Human^™ antibody therapy, in 2010, the Company began a clinical trial program. The first clinical trial program at MD Anderson Cancer Center began treating the sickest cancer patients irrespective of tumor type. Soon thereafter, the Company used the same antibody therapy in various clinical studies at treatment centers around the United States (U.S.) and abroad to investigate the antibody effect in patients that had vascular disease, leukemia, type 2 diabetes, psoriasis or acne.

The Company continues to be subject to a number of risks common to companies in similar stages of development. Principal among these risks are the uncertainties of technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors and protection of proprietary technology. All of these risks are likely to be exacerbated by the outbreak of the novel strain of coronavirus, SARS-CoV-2 (“COVID-19”) and its ongoing impact, which has disrupted our business operations and will continue to do so. We cannot determine at this time the length or severity of these disruptions. The Company’s ability to fund its planned clinical operations, including completion of its planned trials, is expected to depend on the amount and timing of cash receipts from future collaboration or product sales and/or financing transactions. On December 30, 2020, the Company entered into a clinical manufacturing agreement and a clinical trial service agreement with Janssen Biotech Inc. The Company believes that its cash and cash equivalents of $241.5 million at March 31, 2020, as well as revenue generated from the Janssen contracts will enable the Company to achieve several major inflection points, including potential new clinical studies with our lead product candidate. We expect to have sufficient cash through one year from the report issuance date.

Significant Accounting Policies

Basis of Presentation

These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“US GAAP”). In the opinion of management, the accompanying consolidated financial statements reflect all adjustments (consisting only of normal recurring items) considered necessary to present fairly the Company’s financial position at March 31, 2020 and December 31, 2019, the results of its operations and comprehensive loss for the three month periods ended March 31, 2020 and 2019, and the cash flows for the three month periods ended March 31, 2020 and 2019.

Basis of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation.

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.

Revenue

Revenue from Janssen Agreements

The Company recognizes revenues from its Janssen Agreements as follows.

The Company entered into its clinical manufacturing and clinical trial services arrangements in connection with its sale of certain intellectual property on December 30, 2019. These contracts commenced January 1, 2020. While these agreements are not considered contracts with a customer based on the terms thereof, we are applying the revenue recognition guidance by analogy.

XBiotech is still in the research and development phase; however, the eventual output of the Company’s intended ordinary activities will be the licensing of intellectual property and/or sale of commercialized compounds for use in pharmaceutical treatment of disease, not the performance of manufacturing of development stage compounds or clinical trials for others. Although Janssen is not a customer, as these services are not the output of XBiotech’s ordinary activities, the Company evaluated the terms of the agreements and has analogized to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (“ASC 606”) for clinical manufacturing and clinical trial services revenue recognition.

Under ASC 606, an entity recognizes revenue when (or as) its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606 (or for those analogized to it), the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts (including by analogy) when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the counterparty. At contract inception, once the contract is determined to be within the scope of or analogized to ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Manufacturing Revenue

We have a Clinical Manufacturing Agreement that we account for by analogy to ASC 606, under which we agreed to manufacture bermekimab for use by Janssen in clinical trials, in exchange for payments of $4.5 million per quarter, paid in advance, for up to two years, though Janssen may terminate the contract for any reason with 60-days’ notice. Quantities are estimated for the two-year period, but are only binding on the Company and Janssen for the next four months of each period, other than by the 60-day notice termination. If, during any calendar quarter, the Company fails to deliver all of the Clinical Products ordered by Janssen, subject to our agreed upon capacity, the next quarter’s fee is reduced proportionately for the shortfall volume. Negative adjustments may also occur for delivered Clinical Products that do not meet quality specifications, though we expect to meet these standards.

We received payment of $4.5 million from Janssen based on billing schedules established in the contract on December 30, 2019 for manufacturing in the first quarter of 2020. Due to the coronavirus pandemic, the Company failed to fully complete the manufacture of drugs specified for the March purchase order due to supply disruptions for the syringes used to hold the manufactured compound. In addition, due to the pandemic, Janssen requested that we delay shipment of volumes for which we had completed manufacturing. We recognized revenue for those volumes held at Janssen’s request, as they are segregated for future delivery. $1.5 million has been recorded as deferred revenue to a future period for the volumes that were not completed due to the syringe shortage until they are completed and delivered. We received the syringe shipment in April, and currently anticipate fulfilling all production volumes and returning to normal manufacturing capabilities by the third quarter of 2020; however, due to the uncertainty associated with the pandemic and related mitigation efforts, it is possible this assessment could change in future periods.

Clinical Trial Service Revenue

On December 30, 2019, we entered into a Transition Services Agreement with Janssen. Pursuant to the Transition Services Agreement, the Company has agreed to continue operational management, on a fee-for-service basis, of two ongoing clinical trials related to bermekimab. The arrangement may continue as long as the clinical trials are ongoing; however, Janssen may terminate the contract at any time with thirty days’ notice.

We have determined that XBiotech is a principal with regard to the single performance obligation for the series of clinical trial services. In consideration for all of the services to be provided, for each calendar quarter during the term of the Transition Services Agreement, Janssen pays the Company for all third party costs incurred (such as for third party clinical trial site costs) plus a markup of 30%, which we recognize on a gross basis as the principal in the arrangement with Janssen. Those amounts relate directly to the Company’s efforts to provide clinical trial services in the respective month, and are allocated to that month’s services. As at March 31, 2020, the Company has recorded $7.5 million Pass-Through Costs and $9.7 million gross Clinical Trial Service Revenue.

Our clinical trial services were unaffected by the coronavirus pandemic during the first quarter of 2020. However, the timelines for future clinical trial services could be extended in the future as a result of the pandemic, which could delay or otherwise adversely affect our revenue. Because our fees are directly related to third party costs of our vendors, our clinical trial service revenues in future periods are likely to be affected by our vendors’ ability to operate and the activities of trial candidates due to the effects of the pandemic and mitigating activities. Our first quarter results may not be indicative of future revenues or costs associated with these clinical trials.

Research and Development Costs

All research and development costs are charged to expense as incurred. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract clinical trial research services, the costs of laboratory consumables, equipment and facilities, license fees and other external costs. Costs incurred to acquire licenses for intellectual property to be used in research and development activities with no alternative future use are expensed as incurred as research and development costs.

Share-Based Compensation

The Company accounts for its share-based compensation awards in accordance with ASC Topic 718, Compensation-Stock Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the board of directors for their services on the board of directors, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. To determine the fair value of its common stock, the Company uses the closing price of the Company’s common stock as reported by NASDAQ. For awards subject to service-based vesting conditions, the Company recognizes share-based compensation expense, equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur rather than on an estimated basis.

Share-based compensation expense recognized for the three months ended March 31, 2020 and 2019 was included in the following line items on the Consolidated Statements of Operations (in thousands).

	Three Months Ended
	March 31,
	2020		2019
Research and development	$	533	$	295
General and administrative		2,144		275
Total share-based compensation expense		779		-
Research and development	$	3,456	$	570

The fair value of each option is estimated on the date of grant using the Black-Scholes method with the following assumptions:

	Three Months Ended
	March 31,
	2020			2019
Dividend yield		-			-
Expected volatility	88%	-	91%	80%	-	82%
Risk-free interest rate	0.5%	-	1.87%	2.46%	-	2.64%
Expected life (in years)	6.25	-	10	5.75	-	10
Weighted-average grant date fair value per share		$12.08			$3.92

Cash and Cash Equivalents

The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consisted primarily of cash on deposit in U.S., German, Swiss, Japanese and Canadian banks. Cash and cash equivalents are stated at cost which approximates fair value.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.

Fair Value Measurements

The consolidated financial statements include financial instruments for which the fair market value of such instruments may differ from amounts reflected on a historical cost basis. Financial instruments of the Company consist of cash deposits, accounts and other receivables, accounts payable, and certain accrued liabilities. These financial instruments are held at cost, which generally approximates fair value due to their short-term nature.

The Company follows ASC Topic 820, Fair Value Measurements and Disclosures, which establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market date (observable inputs) and the Company’s own assumptions (unobservable inputs). The hierarchy consists of three levels:

•

Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities.

•

Level 2—Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

•

Level 3—Unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

At March 31, 2020 and December 31, 2019, the Company did not have any assets or liabilities that are measured at fair value on a recurring basis. The carrying amounts reflected in the balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values at March 31, 2020 and December 31, 2019, due to their short-term nature.

Property and Equipment

Property and equipment, which consists of land, construction in process, furniture and fixtures, computers and office equipment, scientific equipment, leasehold improvements, vehicles and building are stated at cost and depreciated over the estimated useful lives of the assets, with the exception of land and construction in process which are not depreciated, using the straight line method. The useful lives are as follows:


•   Furniture and fixtures	7 years

•   Office equipment	5 years

•   Leasehold improvements	Shorter of asset’s useful life or remaining lease term

•   Scientific equipment	5 years

•   Vehicles	5 years

•   Mobile facility	27.5 years

•   Building	39 years

Costs of major additions and betterments are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized.

Impairment of Long-Lived Assets

The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of these assets is assessed based on undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. The Company has not recognized any impairment through March 31, 2020.

Income Taxes

Income taxes are recorded in accordance with ASC 740, Accounting for Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company makes estimates and judgments in determining the need for a valuation allowance, including the estimation of its taxable income or loss for the quarter ended March 31, 2020. Realization of deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets certain deferred tax assets with a valuation allowance. The Company may in the future determine that certain deferred tax assets are more-likely-than-not be realized, in which case the Company will reduce its valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, the Company may recognize a benefit from income taxes in its statement of operations in that period.

ASC 740 clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods and disclosure. The Company’s policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of tax expense.

Foreign Currency Transactions

Certain transactions are denominated in a currency other than the Company’s functional currency of the U.S. dollar, and the Company generates assets and liabilities that are fixed in terms of the amount of foreign currency that will be received or paid. At each balance sheet date, the Company adjusts the assets and liabilities to reflect the current exchange rate, resulting in a translation gain or loss. Transaction gains and losses are also realized upon a settlement of a foreign currency transaction in determining net loss for the period in which the transaction is settled.

Comprehensive Income (Loss)

ASC Topic 220, Comprehensive Income, requires that all components of comprehensive income (loss), including net income (loss), be reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments.

Segment and Geographic Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company’s operations and manage its business as one operating segment. Substantially all of the Company’s operations are in the U.S. geographic segment.

Net Loss Per Share

Net income/loss per share (“EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net income/loss by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which include stock options, is computed using the treasury stock method.

Subsequent Events

The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in its consolidated financial statements. We have evaluated subsequent events through the date of filing this Form 10-Q.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements

In February 2016, the FASB established Topic 842, Leases, by issuing Accounting Standards Update (ASU) No. 2016-02, which supersedes ASC 840, Leases, and requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 201801, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 201811, Targeted Improvements. Topic 842, as amended (the "new lease standard") establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The effective date of the new guidance is for the Company’s first quarter of fiscal year 2019. The FASB has approved an optional, alternative method to adopt the lease standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted the new standard effective January 1, 2019, using the alternative method. The Company did not have a cumulative adjustment impacting retained earnings. Adoption of the lease standard did not have a material impact on the Company’s consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This ASU requires instruments measured at amortized cost to be presented at the net amount expected to be collected. Entities are also required to record allowances for available-for-sale debt securities rather than reduce the carrying amount. On November 15, 2019, the FASB delayed the effective date of the standard for certain small public companies and other private companies. As amended, the effective date of ASC Topic 326 was delayed until fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, as well as private companies and not-for-profit entities. The Company expects that the adoption will not have a material impact on its consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The standard will become effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. We early adopted ASU 2019-12 during the quarter ended March 31, 2020. The adoption of ASU 2019-12 resulted in no material impact to the Company's financial statements.

Revenue

On December 30, 2019, the Company entered into a Transition Services Agreement with Janssen. Pursuant to the Transition Services Agreement, the company has agreed to continue operational management, on a fee-for-service basis, of two ongoing clinical trials related to bermekimab. In consideration for all of the services to be provided, for each calendar quarter during the term of such agreement, Janssen shall pay the Company a fee for such quarter equal to all pass-through costs incurred by the Company during such calendar quarter, plus a markup of 30%. At March 31, 2020, the Company has recorded $7 million of gross revenue under this arrangement with the corresponding expense to clinical services cost of goods sold.

Property and Equipment

Property and equipment consisted of the following as of March 31, 2020 and December 31, 2019 (in thousands):

	March 31, 2020		December 31, 2019
Manufacturing equipment	$	3,420	$	3,492
Winnebago building		19,275		19,406
Other fixed assets		2,339		2,273
Total property and equipment	$	25,034	$	25,171

Common Stock

Pursuant to its Articles, the Company has an unlimited number of shares available for issuance with no par value.

During June 2019, under the Common Shares Purchase Agreement with Piper Jaffray & Co., the Company sold 4.8 million shares of common stock at a price $8.25 per share for total net proceeds of $37.5 million, including the capitalized underwriter’s commission of $2.3 million and other related fees of $0.2 million.

From January through December 2019, 771 thousand shares of common stock were issued upon the exercise of stock options at a price of $2.50 to $15.00 per share for total proceeds of $3.8 million.

On January 4, 2020, XBiotech announced that it had commenced a “modified Dutch auction” tender offer to purchase up to $420,000,000 of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not less than $30.00 nor greater than $33.00 per common share, to the seller in cash. The tender offer expired on February 12, 2020.

On February 19, 2020, the Company announced the final results of its “modified Dutch Auction” tender offer. The Company accepted for purchase 14,000,000 shares of its common stock, $0.01 par value per share, at a price of $30 per share, for an aggregate cost of approximately $420 million, excluding fees and expenses related to the tender offer. These shares represented approximately 32.67 percent of the shares outstanding. $6.66 per share or total of $93.24 million of these share repurchases have been classified to reduce common stock and $23.34 per share or total of $326.76 million of these share repurchases have been classified to reduce retained earnings in the accompanying consolidated balance sheet as of March 31, 2020.

From January through March 2020, 1.3 million shares of common stock were issued upon the exercise of stock options at a price of $2.94 to $19.09 per share for total proceeds of $7.9 million.

Common Stock Options

On November 11, 2005 and April 1, 2015, the board of directors of the Company adopted stock option plans (“the Plans”) pursuant to which the Company may grant incentive stock options to directors, officers, employees or consultants of the Company or an affiliate or other persons as the Compensation Committee may approve.

All options are non-transferable and may be exercised only by the participant, or in the event of the death of the participant, a legal representative until the earlier of the options’ expiry date or the first anniversary of the participant’s death, or such other date as may be specified by the Compensation Committee.

The term of the options is at the discretion of the Compensation Committee, but may not exceed 10 years from the grant date. The options expire on the earlier of the expiration date or the date three months following the day on which the participant ceases to be an officer or employee of or consultant to the Company, or in the event of the termination of the participant with cause, the date of such termination. Options held by non-employee Directors have an exercise period coterminous with the term of the options.

The number of common shares reserved for issuance to any one person pursuant to the Plan adopted in 2005 may not, in aggregate, exceed 5% of the total number of outstanding common shares. The exercise price per common share under each option is the fair market value of such shares at the time of the grant. Upon stock option exercise, the Company issues new shares of common stock.

A summary of changes in common stock options issued under the Plans is as follows:

	Options			Exercise Price			Weighted-Average Exercise Price
Options outstanding at December 31, 2019		6,965,730		$2.71	-	$21.99		6.09
Granted		50,500		8.89	-	21.8		15.40
Exercised		(1,333,294	)	2.94	-	19.09		5.94
Forfeitures		(12,167	)	4.95	-	10.36		8.13
Options outstanding at March 31, 2020		5,670,769		$2.71	-	$21.99		6.17

As of March 31, 2020, there was approximately $13.6 million of unrecognized compensation cost, related to stock options granted under the Plans which will be amortized to stock compensation expense over the next 1.66 years.

Net Income/Loss Per Share

The following summarizes the computation of basic and diluted net income/loss per share for the quarter ended March 31, 2020 and 2019 (in thousands, except share and per share data):

	Three Months Ended March 31,
	2020			2019
Net loss	$	(14	)	$	(5,864	)
Weighted-average number of common shares—basic and diluted		36,169,493			35,977,422
Net loss per share—basic and diluted	$	(0.00	)	$	(0.16	)

Income Taxes

The Company did not record a tax provision during the three months ended March 31, 2019 due to the Company having no revenues or income prior to December 2019. During the three months ended March 31, 2020, the Company recorded an income tax benefit of $352 thousand. The forecasted 2020 annual effective tax rate of 12.5% has been applied to net income before income taxes for the three months ended March 31, 2020. Further adjustments have been made for the tax effect of discrete tax benefits of stock compensation realized during the current period, resulting in a 96.4% effective tax rate for the three months ended March 31, 2020.

The difference in the 27% Canadian statutory tax rate and the annual forecasted effective tax rate is primarily a result of the jurisdictional mix of earnings and losses, valuation allowances, and permanently disallowed stock compensation expenses. The Company maintains a valuation allowance against all deferred tax assets in Switzerland, Germany and Japan and certain deferred tax assets in the US and Canada in the current and forecasted annual periods that we concluded are not more-likely-than-not to be realizable.

Subsequent Events

The ongoing COVID-19 pandemic is disrupting our business operations, which we expect to continue throughout the remainder of 2020 and possibly beyond. We have experienced actual disruption to our supply chain regarding our ability to obtain syringes, and we have experienced or may experience difficulty obtaining masks, gloves and stoppers for vials, all of which are required in our manufacturing and/or clinical and drug discovery operations. Disruptions to clinical activities have already impacted our contractual arrangements with Janssen, causing Janssen to reduce its drug manufacturing orders under the clinical manufacturing agreement. Although we concluded that COVID-19 did not result in material adverse impacts on the Company’s results of operations and financial position at March 31, 2020, if supply disruptions and purchase reductions continue, our clinical manufacturing revenue will be, and our clinical trial service revenue could be, adversely impacted. In addition, stay-at-home orders and social distancing restrictions imposed by national, state and local governments have required adjustments to staffing levels and may impact the willingness of employees to work in laboratory, manufacturing and clinical settings, even after these orders and restrictions are relaxed or allowed to expire. Ongoing restrictions and other disruptions related to COVID-19 could delay our efforts to identify, manufacture, enter into clinical studies, seek regulatory approvals or otherwise commercialize any product candidates.

On April 3, 2020, the Company announced the collaboration with BioBridge Global to participate in a U.S. Food and Drug Administration (FDA) investigational program for U.S. blood centers to begin collecting and distributing convalescent plasma from individuals who have recovered from COVID-19. The Company intends to use the blood samples to develop a candidate True Human™ antibody therapy for the disease.

On April 14, 2020, the Company announced that a novel antibody it has discovered that neutralizes interleukin-1 alpha (IL-1⍺) has now been advanced as a product candidate for clinical and commercial development. With the discovery, the Company is on schedule to reenter the clinic trials with a new anti-IL-1⍺ therapy in 2021.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

XBiotech Inc. (“XBiotech” or the “Company) is a pre-market biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. XBiotech is focused on developing its True Human™ pipeline and manufacturing system.

After the Janssen Transaction in December 2019, as of March 31, 2020, we had retained earnings of $243.6 million. We had net losses of $0.3 million and $5.9 million for the three months ended March 31, 2020 and 2019, respectively. During the next two years, we expect that the revenues from Janssen Transaction will generate enough cash for our research and development activities. However, we expect to incur significant and increasing operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical testing and clinical trials and seek regulatory approval and eventual commercialization. In addition to these increasing research and development expenses, we expect general and administrative costs to increase as we continue to operate as a public company, particularly following the end of the 2019 fiscal year when we lost our status as an emerging growth company and be required to comply with additional obligations from which we are currently exempt, including the auditor attestation requirement for internal controls. We will need to generate significant revenues to achieve or sustain profitability, and we may never do so. As of March 31, 2020, we had 63 employees.

Impact of COVID-19 Pandemic

During the first quarter of 2020, we were subject to challenging social and economic conditions created as a result of the novel strain of coronavirus, SARS-CoV-2 (“COVID-19”). The resulting impact of the COVID-19 outbreak has created various impacts to our operations as a result of taking necessary precautions for essential personnel to operate safely both in person as well as remotely, disruptions in our supply chain and delays requested by Janssen in shipping drug product under our clinical manufacturing agreement.

We are currently operating our facilities at less than normal levels. Our office-based employees have been working from home since early March 2020, while ensuring essential staffing levels in our operations remain in place, including maintaining key personnel in our laboratories and manufacturing facilities. The Company considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on the Company’s results of operations and financial position at March 31, 2020; however, this may not continue to be the case in future quarters . In addition to the delays we have already experienced in shipping drug product, it is possible that the COVID-19 pandemic and response efforts may adversely impact our future ability to manufacture clinical drugs for Janssen, which could have a material adverse impact on our results of operations or financial position during the remainder of 2020. In addition, having a significant number of employees working remotely could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions.

While we are currently continuing the clinical trials under the transition services agreement with Janssen, we expect that COVID-19 precautions may directly or indirectly impact the timeline for some of the clinical trials, which could delay or otherwise adversely affect our revenue and adversely impact our financial position. To help mitigate the impact to our clinical trials, we are pursuing innovative approaches such as remote monitoring, remote patient visits and supporting home infusions.

We currently anticipate fulfilling all production volumes and returning to normal manufacturing capabilities under the clinical manufacturing agreement by the third quarter of 2020; however, due to the uncertainty associated with the pandemic and related mitigation efforts, it is possible this assessment could change in future periods as our manufacturing capabilities and Janssen’s purchase orders may continue to be negatively impacted.

Revenues

Prior to receiving payments under the clinical manufacturing agreement entered into in connection with the Janssen Transaction, we had not generated any revenue. Under this clinical manufacturing agreement, we manufacture bermekimab for use by Janssen in clinical trials, in exchange for fixed payments, paid in quarterly installments through 2021. As of March 31, 2020, we have recorded $3 million as manufacturing revenue.

In addition, we entered into a transition services agreement under which we agreed to continue operational management, on a fee-for-service basis, of certain ongoing clinical trials related to bermekimab. In consideration for all of the services to be provided, for each calendar quarter during the term of the transition services agreement, Janssen shall pay the Company a fee for such quarter equal to all Pass-Through Costs incurred by the Company during such calendar quarter, plus a markup of 30%. As at March 31, 2020, the Company has recorded more than $7 million Pass-Through Costs and $9.7 million gross Clinical Trial Service Revenue.

Our ability to generate any additional revenue and/or to become profitable (or sustain any profitability) depends on our ability to successfully commercialize any product candidates we may advance in the future. On April 14, 2020, the Company announced that a novel antibody it has discovered that neutralizes interleukin-1 alpha (IL-1⍺) has now been advanced as a product candidate for clinical and commercial development. With the discovery, the Company is on schedule to reenter the clinic with a new anti-IL-1⍺ therapy in 2021. However, we are not able to estimate at this time the potential impact of the COVID-19 pandemic on our estimated timelines. It is possible that measures implemented to date or that may be implemented or re-implemented in the future by governmental authorities and/or our business partners in response to the pandemic may extend the timelines related to our development, clinical and commercial activities, which delays may be material and may adversely affect our revenues for future quarters , the current fiscal year or beyond.

Research and Development Expenses

Research and development expense consists of expenses incurred in connection with identifying and developing our drug candidates. These expenses consist primarily of salaries and related expenses, stock-based compensation, the purchase of equipment, laboratory and manufacturing supplies, facility costs, costs for preclinical and clinical research, development of quality control systems, quality assurance programs and manufacturing processes. We charge all research and development expenses to operations as incurred.

Clinical development timelines, likelihood of success and total costs vary widely. We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates. From inception through March 31, 2020, we have recorded total research and development expenses, including share-based compensation, of $211.0 million. Our total research and development expenses for the three months ended March 31, 2020 and 2019 were $1.2 million and $4.5 million, respectively. Share-based compensation accounted for $533 thousand and $295 thousand for the three months ended March 31, 2020 and 2019, respectively.

Research and development expenses, as a percentage of total operating expenses for the three months ended March 31, 2020 and 2019 were 22% and 78%, respectively. The percentages, excluding stock-based compensation, for the three months ended March 31, 2020 and 2019, were 25% and 81%, respectively.

The clinical development costs may further increase going forward with potentially more advanced studies in the future as we evaluate our clinical data and pipeline.

Based on the results of our preclinical studies, we anticipate that we will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success and commercial potential. For research and development candidates in early stages of development, it is premature to estimate when material net cash inflows from these projects might occur. In addition, our ability to conduct research and other laboratory activities, to engage in clinical studies and to pursue regulatory approvals may be delayed or otherwise adversely impacted by measures implemented by governmental authorities and/or our business partners in response to the COVID-19 pandemic.

General and Administrative Expenses

General and administrative expense consists primarily of salaries and related expenses for personnel in administrative, finance, business development and human resource functions, as well as the legal costs of pursuing patent protection of our intellectual property and patent filing and maintenance expenses, stock–based compensation, and professional fees for legal services. Our total general and administration expenses for the three months ended March 31, 2020 and 2019 were $4.0 million and $1.3 million, respectively. Share-based compensation accounted for $2.1 million and $0.3 million for the three months ended March 31, 2020 and 2019, respectively.

General and administrative expense, as a percentage of total operating expenses for the three months ended March 31, 2020 and 2019 were 78% and 22%, respectively. The percentages, excluding stock-based compensation, for the three months ended March 31, 2020 and 2019, were 75% and 19%, respectively.

Critical Accounting Policies

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations is based on our financial statements, which have been prepared in conformity with generally accepted accounting principles in the United States (US GAAP). The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and expenses incurred during the reported periods.

We base estimates on our historical experience, known trends and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Our significant accounting policies are more fully described in the notes to our financial statements appearing in this Quarterly Report on Form 10-Q.

Income Taxes

We account for income taxes under the asset and liability method. We record deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We assess the likelihood that deferred tax assets will be realized, and we recognize a valuation allowance if it is more likely than not that some portion of the deferred tax assets will not be realized. This assessment requires judgment as to the likelihood and amounts of future taxable income by tax jurisdiction. To date, we have provided a valuation allowance against our deferred tax assets as we believe the objective and verifiable evidence of our historical pretax net losses outweighs any positive evidence of our forecasted future results. Although we believe that our tax estimates are reasonable, the ultimate tax determination involves significant judgment. We will continue to monitor the positive and negative evidence and will adjust the valuation allowance as sufficient objective positive evidence becomes available.

We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is more likely than not that the position will be sustained upon examination. We recognize potential accrued interest and penalties associated with unrecognized tax positions within our global operations in income tax expense.

Results of Operations

Revenue

Revenue during the three months ended March 31, 2020 and 2019 are summarized as follows (in thousands):

	Three Months Ended March 31,
	2020		2019
Revenue
Manufacturing revenue	$	3,000	$	-
Clinical Trial revenue		9,681		-
Total revenue	$	12,681	$	-

We had not generated any revenue before the year 2020. Under the clinical manufacturing agreement with Janssen, as of March 31, 2020, we have recorded $3 million as manufacturing revenue for January and February, 2020. Clinical trial revenue is based on the transition services agreement under which we agreed to continue operational management, on a fee-for-service basis, of certain ongoing clinical trials related to bermekimab, which includes $7.5 million pass-through expense for two ongoing trials and $2.2 million mark-up revenue. Our first quarter results may not be indicative of future revenues or costs associated with our clinical manufacturing or clinical trial management agreements due to the ongoing impact of the COVID-19 pandemic.

Cost of Goods Sold

Cost of goods sold during the three months ended March 31, 2020 and 2019 are summarized as follows (in thousands):

	Three Months Ended March 31,
	2020		2019
Cost of goods sold
Manufacturing cost	$	2,166	$	-
Clinical trial cost		7,507		-
Total cost of goods sold	$	9,673	$	-

We had not incurred any cost of goods sold before the year 2020. The manufacturing cost was period expense for manufacture, quality assurance and quality control department for January and February, 2020 . Clinical trial cost was the pass-through expense for two ongoing trials and other clinical trial department expense for the three months ended March 31, 2020. Our first quarter results may not be indicative of future revenues or costs associated with our clinical manufacturing or clinical trial management agreements due to the ongoing impact of the COVID-19 pandemic.

Expenses

Research and Development

Research and Development costs are summarized as follows (in thousands):

	Three Months Ended March 31,				Increase			% Increase
	2020		2019		(Decrease)			(Decrease)
Salaries and related expenses	$	321	$	1,166	$	(845	)		-72	%
Laboratory and manufacturing supplies		124		1,242		(1,118	)		-90	%
Clinical trials and sponsored research		-		256		(256	)		-100	%
Stock-based compensation		533		295		238			81	%
Other		177		1,568		(1,391	)		-89	%
Total	$	1,155	$	4,527	$	(3,372	)		-74	%

We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates.

Research and development expenses decreased $3.4 million to $1.2 million for the three months ended March 31, 2020, compared to $4.5 million for the three months ended March 31, 2019. The decrease was mainly due to reclassification of expense. Manufacturing department expenses were reclassed to cost of goods sold as a result of the clinical manufacturing agreement we entered into as part of the Janssen Transaction. Also, we didn’t generate clinical trial expense for the three months ended March 31, 2020, because all such expenses incurred were pursuant to the transition services agreement entered into as part of the Janssen Transaction. As a result, clinical trial department expenses were reclassed to cost of goods sold. Our first quarter results may not be indicative of future revenues or costs associated with our clinical manufacturing or clinical trial management agreements due to the ongoing impact of the COVID-19 pandemic. The stock-based compensation increased due to the new grants to employees and Chief Executive Officer in the fourth quarter of 2019.

General and Administrative

General and administrative costs are summarized as follows (in thousands):

	Three Months Ended March 31,				Increase			% Increase
	2020		2019		(Decrease)			(Decrease)
Salaries and related expenses	$	258	$	254	$	4			2	%
Patent filing expense		139		199		(60	)		-30	%
Stock-based compensation		2,144		275		1,869			680	%
Professional fees		938		184		754			410	%
Other		544		366		178			49	%
Total	$	4,023	$	1,278	$	2,745			215	%

General and administrative expense increased $2.7 million to $4.0 million for the three months ended March 31, 2020, compared to $1.3 million for the three months ended March 31, 2019. The increase was primarily related to stock–based compensation expenses of $2.1 million, due to the new grants to employees and Chief Executive Officer in the fourth quarter of 2019. Also, professional fees increased $0.7 million mainly due to professional and legal fees related to the tender offer completed in February 2020.

Other income (loss)

The following table summarizes other income (loss) (in thousands):

	Three Months Ended March 31,
	2020			2019
Interest income	$	1,898		$	78
Other income		-			9
Foreign exchange gain (loss)		(93	)		(146	)
Total	$	1,805		$	(59	)

The interest income for the three months ended March 31, 2020 and 2019 was mainly from the interest generated from the Company’s Canadian bank account. Foreign exchange gain and loss was mainly due to the fluctuation between the US dollar and the Euro in the three months ended March 31, 2020 compared to the three months ended March 31, 2019.

Liquidity and Capital Resources

Our cash requirements could change materially as a result of the progress of our research and development and clinical programs, licensing activities, acquisitions, divestitures or other corporate developments. In addition, the duration and extent of measures that have been or may in the future be adopted by XBiotech or our business partners, or imposed by governmental authorities, in response to the COVID-19 pandemic may require the use of additional cash resources and adversely impact our liquidity. We are currently unable to estimate the severity or duration of these potential impacts to our liquidity and capital resources.

Since our inception on March 22, 2005 through March, 2020, we have funded our operations principally through private placements and public offerings of equity securities, which have provided aggregate cash proceeds of approximately $307.4 million. We received $675 million in cash proceeds from the Janssen Transaction in the year ended December 31, 2019. We will receive $75 million cash from the same transaction in 2021. The following table summarizes our sources and uses of cash (in thousands):

	Three Months Ended March 31,
Net cash (used in) provided by:	2020			2019
Operating activities	$	(60,673	)	$	(4,677	)
Investing activities		(389	)		(6	)
Financing activities		(412,082	)		741
Effect of foreign exchange rate on cash and cash equivalents		90			138
Net change in cash and cash equivalents	$	(473,054	)	$	(3,804	)

During the three months ended March 31, 2020 and 2019, our operating activities used net cash of $60.7 million and $4.7 million, respectively. The use of net cash in each of these periods primarily resulted from our net losses. The increase in net loss from operations for the three months ended March 31, 2020 as compared to the three months ended March 31, 2019 was mainly due to the $51.1 million income tax payment for 2019.

During the three months ended March 31, 2020 and 2019, our investing activities used net cash of $389 thousand and $6 thousand, respectively. The use of cash was for the purchase of new research and development equipment.

During the three months ended March 31, 2020 and 2019, our financing activities used net cash of $412.1 million and provided net cash proceeds of $0.7 million, respectively. During the three months ended March 31, 2020, employees exercised stock options to purchase a total of 1.3 million shares of our common stock for approximately $7.9 million in net proceeds. On February 19, 2020, we used approximately $420 million to purchase 14,000,000 common shares at a price of $30.00 per share, relating to the tender offer completed in February 2020. During the three months ended March 31, 2019, employees exercised stock options to purchase a total of 190 thousand shares of our common stock for approximately $0.5 million in net proceeds. In this period, the Company also collected $0.2 million of its subscription receivable balance.

We expect to continue to incur operating losses in the future. Although we are currently receiving clinical manufacturing revenue and clinical trial service revenue from Janssen, we will not receive any product revenue until a drug candidate has been approved by the FDA, EMA or similar regulatory agencies in other countries and successfully commercialized. As of March 31, 2020, our principal sources of liquidity were our cash and cash equivalents, which totaled approximately $241.5 million. The ongoing impact of COVID-19 may delay or reduce our expected revenues from the Janssen Transaction. If we determine in the future that we require additional capital, we may face difficulties in conducting common stock offerings, as a result of market volatility caused by continued effects of COVID-19 affecting the global economy.

Off-Balance Sheet Arrangements

Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.

Item 3.

Quantitative and Qualitative Disclosure of Market Risks

The Company is not currently exposed to material market risk arising from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. The Company has no need to hedge against any of the foregoing risks and therefore currently engages in no hedging activities.

Item 4.

Controls and Procedures

Management's Evaluation of our Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and are operating in an effective manner.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended March 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

PART II - OTHER INFORMATION

Item 1. Risk Factors

There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2019, except for the following:

Our business may be adversely affected by the ongoing COVID-19 pandemic.

Beginning in late 2019, the outbreak of COVID-19 has evolved into a global pandemic that is disrupting our business operations, which we expect to continue throughout the remainder of 2020 and possibly beyond. Depending upon the length and severity of the pandemic, which cannot be predicted, we may continue to experience disruptions that could materially and adversely impact our business including:

•

In March 2020 we were unable to fully complete the manufacture of drugs specified under our purchase order from Janssen due to an inability to obtain an adequate number of the syringes used to hold the manufactured compound. We also have experienced or may experience difficulty obtaining masks, gloves and stoppers for vials, all of which are required in our manufacturing and/or clinical and drug discovery operations. If these or any other third parties in our supply chain are or continue to be adversely impacted by restrictions resulting from the COVID-19 pandemic, including staffing shortages, production slowdowns, or disruptions in freight and other transportation services and delivery distribution systems, our supply chain may be disrupted, which would limit our ability to manufacture our product candidates for our clinical trials, to meet our obligations to manufacture drugs for Janssen under our clinical manufacturing agreement, or to conduct our research, development and clinical operations.

•

The pandemic has already affected and may continue to affect our obligations and performance under our agreements with Janssen. In addition to the production issues described above caused by the syringe shortage, in March 2020, Janssen reduced its drug manufacturing order and requested that we delay shipment of drugs that we had already completed manufacturing . We cannot predict the likely potential adverse impact of COVID-19 on Janssen’s future purchase orders or our ability to complete the manufacturing required by those purchase orders.

•

Various aspects of our clinical trials could be limited or take longer than expected, including delays or difficulties in enrolling patients in our clinical trials, in clinical trial site initiation, and in recruiting clinical site investigators and clinical site staff; increased rates of patients withdrawing from clinical trials; diversion of healthcare resources away from the conduct of clinical trials; interruption of key clinical trial activities such as clinical trials site data monitoring due to limitations on travel imposed or recommended by governmental authorities; impact on employees and others or interruption of clinical trial visits or study procedures which may impact the integrity of subject data and clinical study endpoints; and interruption or delays in the operations of the FDA and comparable foreign regulatory agencies, which may impact regulatory review and approval timelines.

•

Our office-based employees have been working from home since early March 2020, while we have attempted to maintain essential staffing levels in our operations, including requiring key personnel in our laboratories and manufacturing facilities to remain on-site. Our increased reliance on employees working from home may negatively impact productivity and disrupt, delay, or otherwise adversely impact our business. In addition, working remotely could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our operations. Stay-at-home orders and social distancing restrictions may impact the willingness of employees to work in laboratory, manufacturing and clinical settings, even after these orders and restrictions are relaxed or allowed to expire. These circumstances could delay our efforts to identify, manufacture, enter into clinical studies, seek regulatory approvals or otherwise commercialize any product candidates.

•

The FDA and comparable foreign regulatory agencies may experience disruptions, have slower response times or be under-resourced to continue to monitor our clinical trials or to conduct required activities and review of our product candidates seeking regulatory review and such disruptions could materially affect the development, timing and approval of our product candidates.

•

As a result of market volatility caused by continued effects of COVID-19 affecting the global economy, we may face difficulties raising capital through sales of our common stock or other securities at acceptable prices, on acceptable terms or at all.

The COVID-19 pandemic continues to rapidly evolve. The ultimate impact of the pandemic on us is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, our clinical manufacturing or clinical trial management agreements, the healthcare system or the global economy. Given the uncertainties, we may be unable to maintain operations as planned prior to the COVID-19 pandemic.

Please carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, any of which risks and uncertainties may be further exacerbated by the COVID-19 pandemic and could materially affect our business, financial condition or future results. The risks described in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our Common Stock. Additional risks not currently known or currently material to us may also harm our business.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds

Not Applicable.

Item 3. Defaults upon Senior Securities

Not Applicable.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information.

Not Applicable.

Item 6. Exhibits.

31.1		Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.

31.2		Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.

32.1		Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350.

101		The following financial statements from the XBiotech Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, formatted in Extensive Business Reporting Language (XBRL): (i) condensed consolidated balance sheets, (ii) condensed consolidated statements of operations, (iii) condensed consolidated statements of comprehensive loss, (iv) ) condensed consolidated statements of shareholders’ equity; (v) condensed consolidated statements of cash flows and (vi) notes to condensed consolidated financial statements (detail tagged).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 11, 2020	XBIOTECH INC.

	By:	/S/ John Simard
		John Simard
		President, Chief Executive Officer and Director (Principal Executive Officer)

Date: May 11, 2020	By:	/S/ Queena Han
		Queena Han
		Vice President, Finance and Human Resources, and Secretary (Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 exh_311.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATIONS

I, John Simard, certify that:

1. I have reviewed this quarterly report on Form 10-Q of XBiotech Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 11, 2020

	/S/ John Simard
	John Simard
	Chief Executive Officer and President
	(Principal Executive Officer)

EX-31.2 3 exh_312.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATIONS

I, Queena Han, certify that:

1. I have reviewed this quarterly report on Form 10-Q of XBiotech Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 11, 2020

	/S/ QUEENA HAN
	Queena Han
	Vice President, Finance and Human Resources and Secretary
	(Principal Financial Officer)

EX-32.1 4 exh_321.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of XBiotech Inc. on Form 10-Q for the period ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Simard, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of XBiotech Inc.

	/S/JOHN SIMARD
	John Simard
	Chief Executive Officer and President
	(Principal Executive Officer)
	Date: May 11, 2020

In connection with the Quarterly Report of XBiotech Inc. on Form 10-Q for the period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Queena Han, Vice President of Finance, Human Resources and Secretary of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of XBiotech Inc.

	/S/ QUEENA HAN
	Queena Han
	Vice President, Finance and Human Resources and Secretary
	(Principal Financial Officer)
	Date: May 11, 2020

EX-101.INS 5 xbit-20200331.xml XBRL INSTANCE FILE false --12-31 Q1 2020 2020-03-31 10-Q 0001626878 28852927 Yes false Accelerated Filer Yes XBiotech Inc. false true Common Stock, no par value xbit

5649000

2149000

9681000

1715000

49361000

1056000

1371000

4180000

-16000

-106000

3456000

570000

533000

295000

2144000

275000

779000

358373000

816877000

257896000

716263000

32000

109000

241540000

714594000

15823000

12019000

-473054000

-3804000

0.01

Unlimited

28852927

41519633

242942000

324808000

-76000

-5726000

1500000

4500000

7500000

2166000

7508000

9674000

1500000

443000

558000

602000

-0.16

90000

138000

0.125

0.27

P1Y240D

13600000

-93000

-146000

4023000

1278000

3007000

-366000

-5864000

-352000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt 0; font-size: 10pt"><div style="display: inline; font-weight: bold;">Income Taxes</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Income taxes are recorded in accordance with ASC <div style="display: inline; font-style: italic; font: inherit;">740,</div> <div style="display: inline; font-style: italic;">Accounting for Income Taxes</div> (“ASC <div style="display: inline; font-style: italic; font: inherit;">740”</div>), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than <div style="display: inline; font-style: italic; font: inherit;">not</div> that some or all of the deferred tax assets will <div style="display: inline; font-style: italic; font: inherit;">not</div> be realized.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company makes estimates and judgments in determining the need for a valuation allowance, including the estimation of its taxable income or loss for the quarter ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020. </div>Realization of deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets certain deferred tax assets with a valuation allowance. The Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>in the future determine that certain deferred tax assets are more-likely-than-<div style="display: inline; font-style: italic; font: inherit;">not</div> be realized, in which case the Company will reduce its valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, the Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>recognize a benefit from income taxes in its statement of operations in that period.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></div> <div style=" font-size: 10pt; text-indent: 27.8pt; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">ASC <div style="display: inline; font-style: italic; font: inherit;">740</div> clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position <div style="display: inline; font-style: italic; font: inherit;"> may </div>be recognized when it is more likely than <div style="display: inline; font-style: italic; font: inherit;">not</div> that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods and disclosure. The Company’s policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of tax expense.</div></div></div>

3793000

3470000

99000

9681000

-47640000

-2815000

-311000

-3000000

-3000

3793000

-489000

-230000

1898000

78000

11291000

61246000

358373000

816877000

10235000

60190000

-412082000

741000

-389000

-6000

-60673000

-4677000

-14000

-5864000

1805000

-59000

5178000

5805000

-2171000

-5805000

90000

138000

9000

389000

6000

Unlimited

1179000

1669000

4500000

3800000

7900000

7918000

200000

3420000

3492000

19275000

19406000

2339000

2273000

25034000

25171000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">March 31, 2020</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">December 31, 2019</td> <td style="font-size: 10pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt; text-align: left">Manufacturing equipment</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">3,420</div></td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">3,492</div></td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Winnebago building</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">19,275</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">19,406</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other fixed assets</td> <td style="font-size: 10pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">2,339</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">2,273</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total property and equipment</td> <td style="font-size: 10pt; border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">25,034</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">25,171</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> </tr> </table></div>

P7Y

P5Y

P27Y182D

P39Y

1155000

4527000

104156000

430929000

9700000

3000000

9681000

12681000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Revenue</div></div> <div style=" margin: 0pt 0; font-size: 10pt"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue from Janssen Agreements</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.5in"> </div> <div style=" margin: 0pt 0 0pt 0.5in; font-size: 10pt">The Company recognizes revenues from its Janssen Agreements as follows.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company entered into its clinical manufacturing and clinical trial services arrangements in connection with its sale of certain intellectual property on <div style="display: inline; font-style: italic; font: inherit;"> December 30, 2019. </div>These contracts commenced <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2020. </div>While these agreements are <div style="display: inline; font-style: italic; font: inherit;">not</div> considered contracts with a customer based on the terms thereof, we are applying the revenue recognition guidance by analogy.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">XBiotech is still in the research and development phase; however, the eventual output of the Company’s intended ordinary activities will be the licensing of intellectual property and/or sale of commercialized compounds for use in pharmaceutical treatment of disease, <div style="display: inline; font-style: italic; font: inherit;">not</div> the performance of manufacturing of development stage compounds or clinical trials for others. Although Janssen is <div style="display: inline; font-style: italic; font: inherit;">not</div> a customer, as these services are <div style="display: inline; font-style: italic; font: inherit;">not</div> the output of XBiotech’s ordinary activities, the Company evaluated the terms of the agreements and has analogized to Accounting Standards Codification, Topic <div style="display: inline; font-style: italic; font: inherit;">606,</div> <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers </div>(“ASC <div style="display: inline; font-style: italic; font: inherit;">606”</div>) for clinical manufacturing and clinical trial services revenue recognition.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Under ASC <div style="display: inline; font-style: italic; font: inherit;">606,</div> an entity recognizes revenue when (or as) its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC <div style="display: inline; font-style: italic; font: inherit;">606</div> (or for those analogized to it), the entity performs the following <div style="display: inline; font-style: italic; font: inherit;">five</div> steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the <div style="display: inline; font-style: italic; font: inherit;">five</div>-step model to contracts (including by analogy) when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the counterparty. At contract inception, once the contract is determined to be within the scope of or analogized to ASC <div style="display: inline; font-style: italic; font: inherit;">606,</div> we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Manufacturing Revenue</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><div style="display: inline; background-color: white">We have a Clinical Manufacturing Agreement that we account for by analogy to ASC <div style="display: inline; font-style: italic; font: inherit;">606,</div> under which we agreed to manufacture bermekimab for use by Janssen in clinical trials, in exchange for payments of <div style="display: inline; font-style: italic; font: inherit;">$4.5</div> million per quarter, paid in advance, for up to <div style="display: inline; font-style: italic; font: inherit;">two</div> years, though Janssen <div style="display: inline; font-style: italic; font: inherit;"> may </div>terminate the contract for any reason with <div style="display: inline; font-style: italic; font: inherit;">60</div>-days’ notice. Quantities are estimated for the <div style="display: inline; font-style: italic; font: inherit;">two</div>-year period, but are only binding on the Company and Janssen for the next <div style="display: inline; font-style: italic; font: inherit;">four</div> months of each period, other than by the <div style="display: inline; font-style: italic; font: inherit;">60</div>-day notice termination. If, during any calendar quarter, the Company fails to deliver all of the Clinical Products ordered by Janssen, subject to our agreed upon capacity, the next quarter’s fee is reduced proportionately for the shortfall volume. Negative adjustments <div style="display: inline; font-style: italic; font: inherit;"> may </div>also occur for delivered Clinical Products that do <div style="display: inline; font-style: italic; font: inherit;">not</div> meet quality specifications, though we expect to meet these standards. </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></div>   <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We received payment of <div style="display: inline; font-style: italic; font: inherit;">$4.5</div> million from Janssen based on billing schedules established in the contract on <div style="display: inline; font-style: italic; font: inherit;"> December 30, 2019 </div>for manufacturing in the <div style="display: inline; font-style: italic; font: inherit;">first</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2020.</div> Due to the coronavirus pandemic, the Company failed to fully complete the manufacture of drugs specified for the <div style="display: inline; font-style: italic; font: inherit;"> March </div>purchase order due to supply disruptions for the syringes used to hold the manufactured compound. In addition, due to the pandemic, Janssen requested that we delay shipment of volumes for which we had completed manufacturing. We recognized revenue for those volumes held at Janssen’s request, as they are segregated for future delivery. <div style="display: inline; font-style: italic; font: inherit;">$1.5</div> million has been recorded as deferred revenue to a future period for the volumes that were <div style="display: inline; font-style: italic; font: inherit;">not</div> completed due to the syringe shortage until they are completed and delivered<div style="display: inline; background-color: white">. We received the syringe shipment in <div style="display: inline; font-style: italic; font: inherit;"> April, </div>and currently anticipate fulfilling all production volumes and returning to normal manufacturing capabilities by the <div style="display: inline; font-style: italic; font: inherit;">third</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2020;</div> however, due to the uncertainty associated with the pandemic and related mitigation efforts, it is possible this assessment could change in future periods.</div></div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><div style="display: inline; background-color: white"> </div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Clinical Trial Service Revenue</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><div style="display: inline; background-color: white">On <div style="display: inline; font-style: italic; font: inherit;"> December 30, 2019, </div>we entered into a Transition Services Agreement with Janssen. Pursuant to the Transition Services Agreement, the Company has agreed to continue operational management, on a fee-for-service basis, of <div style="display: inline; font-style: italic; font: inherit;">two</div> ongoing clinical trials related to bermekimab.</div> The arrangement <div style="display: inline; font-style: italic; font: inherit;"> may </div>continue as long as the clinical trials are ongoing; however, Janssen <div style="display: inline; font-style: italic; font: inherit;"> may </div>terminate the contract at any time with <div style="display: inline; font-style: italic; font: inherit;">thirty</div> days’ notice.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We have determined that XBiotech is a principal with regard to the single performance obligation for the series of clinical trial services. In consideration for all of the services to be provided, for each calendar quarter during the term of the Transition Services Agreement, Janssen pays the Company for all <div style="display: inline; font-style: italic; font: inherit;">third</div> party costs incurred (such as for <div style="display: inline; font-style: italic; font: inherit;">third</div> party clinical trial site costs) plus a markup of <div style="display: inline; font-style: italic; font: inherit;">30%,</div> which we recognize on a gross basis as the principal in the arrangement with Janssen. Those amounts relate directly to the Company’s efforts to provide clinical trial services in the respective month, and are allocated to that month’s services. As at <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020, </div>the Company has recorded <div style="display: inline; font-style: italic; font: inherit;">$7.5</div> million Pass-Through Costs and <div style="display: inline; font-style: italic; font: inherit;">$9.7</div> million gross Clinical Trial Service Revenue.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our clinical trial services were unaffected by the coronavirus pandemic during the <div style="display: inline; font-style: italic; font: inherit;">first</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2020.</div> However, the timelines for future clinical trial services could be extended in the future as a result of the pandemic, which could delay or otherwise adversely affect our revenue. Because our fees are directly related to <div style="display: inline; font-style: italic; font: inherit;">third</div> party costs of our vendors, our clinical trial service revenues in future periods are likely to be affected by our vendors’ ability to operate and the activities of trial candidates due to the effects of the pandemic and mitigating activities. Our <div style="display: inline; font-style: italic; font: inherit;">first</div> quarter results <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be indicative of future revenues or costs associated with these clinical trials.</div></div></div></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap; font-size: 10pt"> </td> <td style="padding-bottom: 1pt; text-align: center; font-size: 10pt; font-weight: bold"> </td> <td colspan="2" style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Options</td> <td style="text-align: center; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"> </td> <td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Exercise Price</td> <td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Weighted-Average<br /> Exercise Price</td> <td style="text-align: center; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt">Options outstanding at December 31, 2019</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">6,965,730</div></td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 5%; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">$2.71</div></td> <td style="width: 4%; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 5%; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">$21.99</div></td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">6.09</div></td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; font-size: 10pt">Granted</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">50,500</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">8.89</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">21.8</div></td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">15.40</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; font-size: 10pt">Exercised</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">(1,333,294</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">2.94</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">19.09</div></td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">5.94</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 20pt; font-size: 10pt">Forfeitures</td> <td style="padding-bottom: 1pt; font-size: 10pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">(12,167</div></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">4.95</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">10.36</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">8.13</div></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; font-size: 10pt">Options outstanding at March 31, 2020</td> <td style="padding-bottom: 1pt; font-size: 10pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">5,670,769</div></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">$2.71</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">$21.99</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">6.17</div></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td> <td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2019</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; width: 70%">Dividend yield</td> <td style="font-size: 10pt; width: 1%"> </td> <td style="font-size: 10pt; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-size: 10pt; text-align: center; width: 4%"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="text-align: center; font-size: 10pt; width: 1%"> </td> <td style="font-size: 10pt; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-size: 10pt; text-align: center; width: 4%"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected volatility</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">88%</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">91%</div></td> <td style="text-align: center; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">80%</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">82%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Risk-free interest rate</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">0.5%</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">1.87%</div></td> <td style="text-align: center; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">2.46%</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">2.64%</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected life (in years)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">6.25</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">10</div></td> <td style="text-align: center; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">5.75</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">10</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Weighted-average grant date fair value per share</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">$12.08</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="text-align: center; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">$3.92</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> </tr> </table></div>

3456000

570000

0.88

0.91

0.8

0.82

0.005

0.0187

0.0246

0.0264

12167

50500

12.08

3.92

6965730

5670769

2.71

21.99

6.09

2.71

21.99

6.17

0.05

2.94

19.09

5.94

4.95

10.36

8.13

8.89

21.80

15.40

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Share-Based Compensation </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company accounts for its share-based compensation awards in accordance with ASC Topic <div style="display: inline; font-style: italic; font: inherit;">718,</div> <div style="display: inline; font-style: italic;">Compensation-Stock Compensation</div> (“ASC <div style="display: inline; font-style: italic; font: inherit;">718”</div>). ASC <div style="display: inline; font-style: italic; font: inherit;">718</div> requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the board of directors for their services on the board of directors, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. To determine the fair value of its common stock, the Company uses the closing price of the Company’s common stock as reported by NASDAQ. For awards subject to service-based vesting conditions, the Company recognizes share-based compensation expense, equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur rather than on an estimated basis.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></div>   <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Share-based compensation expense recognized for the <div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div> was included in the following line items on the Consolidated Statements of Operations (in thousands).</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</td> <td style="font-size: 10pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td> <td style="font-size: 10pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt; text-align: left">Research and development</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">533</div></td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">295</div></td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">General and administrative</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">2,144</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">275</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total share-based compensation expense</td> <td style="padding-bottom: 1pt; font-size: 10pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">779</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Research and development</td> <td style="padding-bottom: 2.5pt; font-size: 10pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">3,456</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">570</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The fair value of each option is estimated on the date of grant using the Black-Scholes method with the following assumptions:</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td> <td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2019</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; width: 70%">Dividend yield</td> <td style="font-size: 10pt; width: 1%"> </td> <td style="font-size: 10pt; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-size: 10pt; text-align: center; width: 4%"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="text-align: center; font-size: 10pt; width: 1%"> </td> <td style="font-size: 10pt; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-size: 10pt; text-align: center; width: 4%"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected volatility</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">88%</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">91%</div></td> <td style="text-align: center; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">80%</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">82%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Risk-free interest rate</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">0.5%</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">1.87%</div></td> <td style="text-align: center; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">2.46%</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">2.64%</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected life (in years)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">6.25</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">10</div></td> <td style="text-align: center; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">5.75</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">10</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Weighted-average grant date fair value per share</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">$12.08</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="text-align: center; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">$3.92</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> </tr> </table> </div></div></div></div></div></div></div></div></div></div>

P10Y

P6Y91D

P10Y

P5Y273D

P10Y

8.25

2.50

2.94

19.09

41519

28853

35900000

36090000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; min-width: 700px;"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">2.</div></div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Significant Accounting Policies</div></td> </tr> </table> <div style=" margin: 0pt 0; font-size: 10pt"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Basis of Presentation </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“US GAAP”). In the opinion of management, the accompanying consolidated financial statements reflect all adjustments (consisting only of normal recurring items) considered necessary to present fairly the Company’s financial position at <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>the results of its operations and comprehensive loss for the <div style="display: inline; font-style: italic; font: inherit;">three</div> month periods ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> and the cash flows for the <div style="display: inline; font-style: italic; font: inherit;">three</div> month periods ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt"></div>   <div style=" margin: 0pt 0; font-size: 10pt"><div style="display: inline; font-weight: bold;">Basis of Consolidation</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Use of Estimates </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">  </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Revenue</div></div> <div style=" margin: 0pt 0; font-size: 10pt"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue from Janssen Agreements</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.5in"> </div> <div style=" margin: 0pt 0 0pt 0.5in; font-size: 10pt">The Company recognizes revenues from its Janssen Agreements as follows.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company entered into its clinical manufacturing and clinical trial services arrangements in connection with its sale of certain intellectual property on <div style="display: inline; font-style: italic; font: inherit;"> December 30, 2019. </div>These contracts commenced <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2020. </div>While these agreements are <div style="display: inline; font-style: italic; font: inherit;">not</div> considered contracts with a customer based on the terms thereof, we are applying the revenue recognition guidance by analogy.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">XBiotech is still in the research and development phase; however, the eventual output of the Company’s intended ordinary activities will be the licensing of intellectual property and/or sale of commercialized compounds for use in pharmaceutical treatment of disease, <div style="display: inline; font-style: italic; font: inherit;">not</div> the performance of manufacturing of development stage compounds or clinical trials for others. Although Janssen is <div style="display: inline; font-style: italic; font: inherit;">not</div> a customer, as these services are <div style="display: inline; font-style: italic; font: inherit;">not</div> the output of XBiotech’s ordinary activities, the Company evaluated the terms of the agreements and has analogized to Accounting Standards Codification, Topic <div style="display: inline; font-style: italic; font: inherit;">606,</div> <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers </div>(“ASC <div style="display: inline; font-style: italic; font: inherit;">606”</div>) for clinical manufacturing and clinical trial services revenue recognition.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Under ASC <div style="display: inline; font-style: italic; font: inherit;">606,</div> an entity recognizes revenue when (or as) its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC <div style="display: inline; font-style: italic; font: inherit;">606</div> (or for those analogized to it), the entity performs the following <div style="display: inline; font-style: italic; font: inherit;">five</div> steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the <div style="display: inline; font-style: italic; font: inherit;">five</div>-step model to contracts (including by analogy) when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the counterparty. At contract inception, once the contract is determined to be within the scope of or analogized to ASC <div style="display: inline; font-style: italic; font: inherit;">606,</div> we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Manufacturing Revenue</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><div style="display: inline; background-color: white">We have a Clinical Manufacturing Agreement that we account for by analogy to ASC <div style="display: inline; font-style: italic; font: inherit;">606,</div> under which we agreed to manufacture bermekimab for use by Janssen in clinical trials, in exchange for payments of <div style="display: inline; font-style: italic; font: inherit;">$4.5</div> million per quarter, paid in advance, for up to <div style="display: inline; font-style: italic; font: inherit;">two</div> years, though Janssen <div style="display: inline; font-style: italic; font: inherit;"> may </div>terminate the contract for any reason with <div style="display: inline; font-style: italic; font: inherit;">60</div>-days’ notice. Quantities are estimated for the <div style="display: inline; font-style: italic; font: inherit;">two</div>-year period, but are only binding on the Company and Janssen for the next <div style="display: inline; font-style: italic; font: inherit;">four</div> months of each period, other than by the <div style="display: inline; font-style: italic; font: inherit;">60</div>-day notice termination. If, during any calendar quarter, the Company fails to deliver all of the Clinical Products ordered by Janssen, subject to our agreed upon capacity, the next quarter’s fee is reduced proportionately for the shortfall volume. Negative adjustments <div style="display: inline; font-style: italic; font: inherit;"> may </div>also occur for delivered Clinical Products that do <div style="display: inline; font-style: italic; font: inherit;">not</div> meet quality specifications, though we expect to meet these standards. </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></div>   <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We received payment of <div style="display: inline; font-style: italic; font: inherit;">$4.5</div> million from Janssen based on billing schedules established in the contract on <div style="display: inline; font-style: italic; font: inherit;"> December 30, 2019 </div>for manufacturing in the <div style="display: inline; font-style: italic; font: inherit;">first</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2020.</div> Due to the coronavirus pandemic, the Company failed to fully complete the manufacture of drugs specified for the <div style="display: inline; font-style: italic; font: inherit;"> March </div>purchase order due to supply disruptions for the syringes used to hold the manufactured compound. In addition, due to the pandemic, Janssen requested that we delay shipment of volumes for which we had completed manufacturing. We recognized revenue for those volumes held at Janssen’s request, as they are segregated for future delivery. <div style="display: inline; font-style: italic; font: inherit;">$1.5</div> million has been recorded as deferred revenue to a future period for the volumes that were <div style="display: inline; font-style: italic; font: inherit;">not</div> completed due to the syringe shortage until they are completed and delivered<div style="display: inline; background-color: white">. We received the syringe shipment in <div style="display: inline; font-style: italic; font: inherit;"> April, </div>and currently anticipate fulfilling all production volumes and returning to normal manufacturing capabilities by the <div style="display: inline; font-style: italic; font: inherit;">third</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2020;</div> however, due to the uncertainty associated with the pandemic and related mitigation efforts, it is possible this assessment could change in future periods.</div></div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><div style="display: inline; background-color: white"> </div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Clinical Trial Service Revenue</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"><div style="display: inline; background-color: white">On <div style="display: inline; font-style: italic; font: inherit;"> December 30, 2019, </div>we entered into a Transition Services Agreement with Janssen. Pursuant to the Transition Services Agreement, the Company has agreed to continue operational management, on a fee-for-service basis, of <div style="display: inline; font-style: italic; font: inherit;">two</div> ongoing clinical trials related to bermekimab.</div> The arrangement <div style="display: inline; font-style: italic; font: inherit;"> may </div>continue as long as the clinical trials are ongoing; however, Janssen <div style="display: inline; font-style: italic; font: inherit;"> may </div>terminate the contract at any time with <div style="display: inline; font-style: italic; font: inherit;">thirty</div> days’ notice.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">We have determined that XBiotech is a principal with regard to the single performance obligation for the series of clinical trial services. In consideration for all of the services to be provided, for each calendar quarter during the term of the Transition Services Agreement, Janssen pays the Company for all <div style="display: inline; font-style: italic; font: inherit;">third</div> party costs incurred (such as for <div style="display: inline; font-style: italic; font: inherit;">third</div> party clinical trial site costs) plus a markup of <div style="display: inline; font-style: italic; font: inherit;">30%,</div> which we recognize on a gross basis as the principal in the arrangement with Janssen. Those amounts relate directly to the Company’s efforts to provide clinical trial services in the respective month, and are allocated to that month’s services. As at <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020, </div>the Company has recorded <div style="display: inline; font-style: italic; font: inherit;">$7.5</div> million Pass-Through Costs and <div style="display: inline; font-style: italic; font: inherit;">$9.7</div> million gross Clinical Trial Service Revenue.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Our clinical trial services were unaffected by the coronavirus pandemic during the <div style="display: inline; font-style: italic; font: inherit;">first</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2020.</div> However, the timelines for future clinical trial services could be extended in the future as a result of the pandemic, which could delay or otherwise adversely affect our revenue. Because our fees are directly related to <div style="display: inline; font-style: italic; font: inherit;">third</div> party costs of our vendors, our clinical trial service revenues in future periods are likely to be affected by our vendors’ ability to operate and the activities of trial candidates due to the effects of the pandemic and mitigating activities. Our <div style="display: inline; font-style: italic; font: inherit;">first</div> quarter results <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be indicative of future revenues or costs associated with these clinical trials.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Research and Development Costs </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">All research and development costs are charged to expense as incurred. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract clinical trial research services, the costs of laboratory consumables, equipment and facilities, license fees and other external costs. Costs incurred to acquire licenses for intellectual property to be used in research and development activities with <div style="display: inline; font-style: italic; font: inherit;">no</div> alternative future use are expensed as incurred as research and development costs.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Share-Based Compensation </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company accounts for its share-based compensation awards in accordance with ASC Topic <div style="display: inline; font-style: italic; font: inherit;">718,</div> <div style="display: inline; font-style: italic;">Compensation-Stock Compensation</div> (“ASC <div style="display: inline; font-style: italic; font: inherit;">718”</div>). ASC <div style="display: inline; font-style: italic; font: inherit;">718</div> requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the board of directors for their services on the board of directors, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. To determine the fair value of its common stock, the Company uses the closing price of the Company’s common stock as reported by NASDAQ. For awards subject to service-based vesting conditions, the Company recognizes share-based compensation expense, equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur rather than on an estimated basis.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></div>   <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Share-based compensation expense recognized for the <div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div> was included in the following line items on the Consolidated Statements of Operations (in thousands).</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</td> <td style="font-size: 10pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td> <td style="font-size: 10pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt; text-align: left">Research and development</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">533</div></td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">295</div></td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">General and administrative</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">2,144</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">275</div></td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total share-based compensation expense</td> <td style="padding-bottom: 1pt; font-size: 10pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">779</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Research and development</td> <td style="padding-bottom: 2.5pt; font-size: 10pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">3,456</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font: inherit;">570</div></td> <td style="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The fair value of each option is estimated on the date of grant using the Black-Scholes method with the following assumptions:</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td> <td style="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2019</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; width: 70%">Dividend yield</td> <td style="font-size: 10pt; width: 1%"> </td> <td style="font-size: 10pt; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-size: 10pt; text-align: center; width: 4%"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="text-align: center; font-size: 10pt; width: 1%"> </td> <td style="font-size: 10pt; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-size: 10pt; text-align: center; width: 4%"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center; width: 5%"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected volatility</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">88%</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">91%</div></td> <td style="text-align: center; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">80%</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">82%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Risk-free interest rate</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">0.5%</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">1.87%</div></td> <td style="text-align: center; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">2.46%</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">2.64%</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected life (in years)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">6.25</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">10</div></td> <td style="text-align: center; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">5.75</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">10</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Weighted-average grant date fair value per share</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">$12.08</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="text-align: center; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;">$3.92</div></td> <td style="font-size: 10pt; text-align: center"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Cash and Cash Equivalents </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company considers highly liquid investments with a maturity of <div style="display: inline; font-style: italic; font: inherit;">three</div> months or less when purchased to be cash equivalents. Cash and cash equivalents consisted primarily of cash on deposit in U.S., German, Swiss, Japanese and Canadian banks. Cash and cash equivalents are stated at cost which approximates fair value.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Concentrations of Credit Risk </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any <div style="display: inline; font-style: italic; font: inherit;">one</div> financial institution. These amounts at times <div style="display: inline; font-style: italic; font: inherit;"> may </div>exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any credit losses in such accounts and does <div style="display: inline; font-style: italic; font: inherit;">not</div> believe it is exposed to any significant credit risk on these funds. The Company has <div style="display: inline; font-style: italic; font: inherit;">no</div> off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Fair Value Measurements </div></div> <div style=" font-size: 10pt; text-indent: 30.6pt; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 30.6pt">The consolidated financial statements include financial instruments for which the fair market value of such instruments <div style="display: inline; font-style: italic; font: inherit;"> may </div>differ from amounts reflected on a historical cost basis. Financial instruments of the Company consist of cash deposits, accounts and other receivables, accounts payable, and certain accrued liabilities. These financial instruments are held at cost, which generally approximates fair value due to their short-term nature.</div> <div style=" font-size: 10pt; text-indent: 30.6pt; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 30.6pt"></div>   <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 30.6pt">The Company follows ASC Topic <div style="display: inline; font-style: italic; font: inherit;">820,</div> <div style="display: inline; font-style: italic;">Fair Value Measurements and Disclosures</div>, which establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market date (observable inputs) and the Company’s own assumptions (unobservable inputs). The hierarchy consists of <div style="display: inline; font-style: italic; font: inherit;">three</div> levels:</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 30.6pt"> </div> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 30.6pt"></td> <td style="width: 18.35pt">•</td> <td>Level <div style="display: inline; font-style: italic; font: inherit;">1—Unadjusted</div> quoted prices in active markets for identical assets or liabilities.</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 30.6pt"></td> <td style="width: 18.35pt">•</td> <td>Level <div style="display: inline; font-style: italic; font: inherit;">2—Quoted</div> prices for similar assets and liabilities in active markets, quoted prices in markets that are <div style="display: inline; font-style: italic; font: inherit;">not</div> active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 30.6pt"></td> <td style="width: 18.35pt">•</td> <td>Level <div style="display: inline; font-style: italic; font: inherit;">3—Unobservable</div> inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</td> </tr> </table> <div style=" font-size: 10pt; text-indent: 30.6pt; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 30.6pt">At <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>the Company did <div style="display: inline; font-style: italic; font: inherit;"></div><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"></div></div><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">not</div></div> </div></div>have any assets or liabilities that are measured at fair value on a recurring basis. The carrying amounts reflected in the balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values at <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>due to their short-term nature.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 30.6pt"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Property and Equipment </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Property and equipment, which consists of land, construction in process, furniture and fixtures, computers and office equipment, scientific equipment, leasehold improvements, vehicles and building are stated at cost and depreciated over the estimated useful lives of the assets, with the exception of land and construction in process which are <div style="display: inline; font-style: italic; font: inherit;">not</div> depreciated, using the straight line method. The useful lives are as follows:</div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <table cellspacing="0" cellpadding="0" align="center" style="; border-collapse: collapse; font-size: 10pt; min-width: 700px;"> <tr> <td> </td> <td> </td> </tr> <tr> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">•   Furniture and fixtures</div></td> <td style="vertical-align: bottom"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font: inherit;">7</div> years</div></td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">•   Office equipment</div></td> <td style="vertical-align: bottom"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font: inherit;">5</div> years</div></td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">•   Leasehold improvements</div></td> <td style="vertical-align: bottom"><div style="display: inline; font-size: 10pt">Shorter of asset’s useful life or remaining lease term</div></td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">•   Scientific equipment</div></td> <td style="vertical-align: bottom"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font: inherit;">5</div> years</div></td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td style="vertical-align: top">•   Vehicles</td> <td style="vertical-align: bottom"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font: inherit;">5</div> years</div></td> </tr> <tr> <td> </td> <td> </td> </tr> <tr> <td style="width: 256px">•   Mobile facility</td> <td><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font: inherit;">27.5</div> years</div></td> </tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> </tr> <tr> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">•   Building</div></td> <td style="vertical-align: bottom"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font: inherit;">39</div> years</div></td> </tr> </table> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Costs of major additions and betterments are capitalized; maintenance and repairs, which do <div style="display: inline; font-style: italic; font: inherit;">not</div> improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Impairment of Long-Lived Assets </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic <div style="display: inline; font-style: italic; font: inherit;">360,</div> <div style="display: inline; font-style: italic;">Property, Plant and Equipment</div>. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be recovered. Recoverability of these assets is assessed based on undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> recognized any impairment through <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020.</div></div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"></div>   <div style=" margin: 0pt 0; font-size: 10pt"><div style="display: inline; font-weight: bold;"></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" margin: 0pt 0; font-size: 10pt"><div style="display: inline; font-weight: bold;">Income Taxes</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Income taxes are recorded in accordance with ASC <div style="display: inline; font-style: italic; font: inherit;">740,</div> <div style="display: inline; font-style: italic;">Accounting for Income Taxes</div> (“ASC <div style="display: inline; font-style: italic; font: inherit;">740”</div>), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than <div style="display: inline; font-style: italic; font: inherit;">not</div> that some or all of the deferred tax assets will <div style="display: inline; font-style: italic; font: inherit;">not</div> be realized.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company makes estimates and judgments in determining the need for a valuation allowance, including the estimation of its taxable income or loss for the quarter ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020. </div>Realization of deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets certain deferred tax assets with a valuation allowance. The Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>in the future determine that certain deferred tax assets are more-likely-than-<div style="display: inline; font-style: italic; font: inherit;">not</div> be realized, in which case the Company will reduce its valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, the Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>recognize a benefit from income taxes in its statement of operations in that period.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></div> <div style=" font-size: 10pt; text-indent: 27.8pt; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">ASC <div style="display: inline; font-style: italic; font: inherit;">740</div> clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position <div style="display: inline; font-style: italic; font: inherit;"> may </div>be recognized when it is more likely than <div style="display: inline; font-style: italic; font: inherit;">not</div> that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods and disclosure. The Company’s policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of tax expense.</div></div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 27.8pt"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Foreign Currency Transactions </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Certain transactions are denominated in a currency other than the Company’s functional currency of the U.S. dollar, and the Company generates assets and liabilities that are fixed in terms of the amount of foreign currency that will be received or paid. At each balance sheet date, the Company adjusts the assets and liabilities to reflect the current exchange rate, resulting in a translation gain or loss. Transaction gains and losses are also realized upon a settlement of a foreign currency transaction in determining net loss for the period in which the transaction is settled.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Comprehensive Income (Loss)</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">ASC Topic <div style="display: inline; font-style: italic; font: inherit;">220,</div> <div style="display: inline; font-style: italic;">Comprehensive Income</div>, requires that all components of comprehensive income (loss), including net income (loss), be reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Segment and Geographic Information </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company’s operations and manage its business as <div style="display: inline; font-style: italic; font: inherit;">one</div> operating segment. Substantially all of the Company’s operations are in the U.S. geographic segment.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Net Loss Per Share </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">Net income/loss per share (“EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net income/loss by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which include stock options, is computed using the treasury stock method.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"></div>   <div style=" margin: 0pt 0; font-size: 10pt"><div style="display: inline; font-weight: bold;">Subsequent Events </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in its consolidated financial statements. We have evaluated subsequent events through the date of filing this Form <div style="display: inline; font-style: italic; font: inherit;">10</div>-Q.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements</div></div> <div style=" margin: 0pt 0; font-size: 10pt"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;"><div style="display: inline; text-decoration: underline;">Recently Issued Accounting Pronouncements</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In <div style="display: inline; font-style: italic; font: inherit;"> February 2016, </div>the FASB established Topic <div style="display: inline; font-style: italic; font: inherit;">842,</div> Leases, by issuing Accounting Standards Update (ASU) <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">02,</div> which supersedes ASC <div style="display: inline; font-style: italic; font: inherit;">840,</div> Leases, and requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic <div style="display: inline; font-style: italic; font: inherit;">842</div> was subsequently amended by ASU <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">201801,</div> Land Easement Practical Expedient for Transition to Topic <div style="display: inline; font-style: italic; font: inherit;">842;</div> ASU <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">10,</div> Codification Improvements to Topic <div style="display: inline; font-style: italic; font: inherit;">842,</div> Leases; and ASU <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">201811,</div> Targeted Improvements. Topic <div style="display: inline; font-style: italic; font: inherit;">842,</div> as amended (the "new lease standard") establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than <div style="display: inline; font-style: italic; font: inherit;">12</div> months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The effective date of the new guidance is for the Company’s <div style="display: inline; font-style: italic; font: inherit;">first</div> quarter of fiscal year <div style="display: inline; font-style: italic; font: inherit;">2019.</div> The FASB has approved an optional, alternative method to adopt the lease standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted the new standard effective <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2019, </div>using the alternative method. The Company did <div style="display: inline; font-style: italic; font: inherit;">not</div> have a cumulative adjustment impacting retained earnings. Adoption of the lease standard did <div style="display: inline; font-style: italic; font: inherit;">not</div> have a material impact on the Company’s consolidated financial statements.</div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In <div style="display: inline; font-style: italic; font: inherit;"> June 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">13,</div> Financial Instruments—Credit Losses (Topic <div style="display: inline; font-style: italic; font: inherit;">326</div>): Measurement of Credit Losses on Financial Instruments. This ASU requires instruments measured at amortized cost to be presented at the net amount expected to be collected. Entities are also required to record allowances for available-for-sale debt securities rather than reduce the carrying amount. On <div style="display: inline; font-style: italic; font: inherit;"> November 15, 2019, </div>the FASB delayed the effective date of the standard for certain small public companies and other private companies. As amended, the effective date of ASC Topic <div style="display: inline; font-style: italic; font: inherit;">326</div> was delayed until fiscal years beginning after <div style="display: inline; font-style: italic; font: inherit;"> December 15, 2022 </div>for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, as well as private companies and <div style="display: inline; font-style: italic; font: inherit;">not</div>-for-profit entities. The Company expects that the adoption will <div style="display: inline; font-style: italic; font: inherit;">not</div> have a material impact on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">In <div style="display: inline; font-style: italic; font: inherit;"> December 2019, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">2019</div>-<div style="display: inline; font-style: italic; font: inherit;">12,</div> Income Taxes (Topic <div style="display: inline; font-style: italic; font: inherit;">740</div>): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic <div style="display: inline; font-style: italic; font: inherit;">740.</div> The amendments also improve consistent application of and simplify GAAP for other areas of Topic <div style="display: inline; font-style: italic; font: inherit;">740</div> by clarifying and amending existing guidance. The standard will become effective for interim and annual periods beginning after <div style="display: inline; font-style: italic; font: inherit;"> December 15, 2020, </div>with early adoption permitted. We early adopted ASU <div style="display: inline; font-style: italic; font: inherit;">2019</div>-<div style="display: inline; font-style: italic; font: inherit;">12</div> during the quarter ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020. </div>The adoption of ASU <div style="display: inline; font-style: italic; font: inherit;">2019</div>-<div style="display: inline; font-style: italic; font: inherit;">12</div> resulted in <div style="display: inline; font-style: italic; font: inherit;">no</div> material impact to the Company's financial statements.</div></div>

4800000

1334

190000

771000

1333294

7918000

643000

420000000

14000000

14000

420000000

324808000

-106000

430929000

755631000

242942000

-16000

104155000

347082000

279353000

-255000

-237700000

41398000

280664000

-117000

-243564000

36983000

36169493

35977422

200000 200000 4500000 -102000 -102000 1703000 75000000 75000000 1703000 200000 0.3267 37500000 -420000000 541000 93240000 -326760000 -93240000 -326760000 -420000000 30 33 30 6.66 23.34 102000 0.3 2 2300000 xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0001626878 2019-01-01 2019-03-31 0001626878 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001626878 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001626878 xbit:ClinicalTrialServiceRevenueMember 2019-01-01 2019-03-31 0001626878 xbit:ManufacturingRevenueMember 2019-01-01 2019-03-31 0001626878 srt:MaximumMember 2019-01-01 2019-03-31 0001626878 srt:MinimumMember 2019-01-01 2019-03-31 0001626878 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001626878 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001626878 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001626878 2019-01-01 2019-12-31 0001626878 us-gaap:BuildingMember 2019-01-01 2020-03-31 0001626878 us-gaap:EquipmentMember 2019-01-01 2020-03-31 0001626878 us-gaap:FurnitureAndFixturesMember 2019-01-01 2020-03-31 0001626878 xbit:MobileFacilityMember 2019-01-01 2020-03-31 0001626878 us-gaap:OfficeEquipmentMember 2019-01-01 2020-03-31 0001626878 us-gaap:VehiclesMember 2019-01-01 2020-03-31 0001626878 xbit:EquityDistributionAgreementMember 2019-06-01 2019-06-30 0001626878 xbit:JanssenMember xbit:ClinicalTrialServiceRevenueMember 2019-12-30 2019-12-30 0001626878 xbit:JanssenMember xbit:ManufacturingRevenueMember 2019-12-30 2019-12-30 0001626878 us-gaap:DomesticCountryMember us-gaap:CanadaRevenueAgencyMember 2020-01-01 2020-01-01 0001626878 2020-01-01 2020-03-31 0001626878 us-gaap:EmployeeStockOptionMember xbit:ThePlanMember 2020-01-01 2020-03-31 0001626878 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001626878 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001626878 xbit:JanssenMember xbit:ClinicalTrialServiceRevenueMember srt:MinimumMember 2020-01-01 2020-03-31 0001626878 xbit:JanssenMember xbit:ManufacturingRevenueMember 2020-01-01 2020-03-31 0001626878 xbit:ThePlanMember xbit:AnyOnePersonMember 2020-01-01 2020-03-31 0001626878 xbit:ClinicalTrialServiceRevenueMember 2020-01-01 2020-03-31 0001626878 xbit:ManufacturingRevenueMember 2020-01-01 2020-03-31 0001626878 srt:MaximumMember 2020-01-01 2020-03-31 0001626878 srt:MinimumMember 2020-01-01 2020-03-31 0001626878 srt:WeightedAverageMember 2020-01-01 2020-03-31 0001626878 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001626878 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001626878 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001626878 2020-02-19 2020-02-19 0001626878 us-gaap:CommonStockMember 2020-02-19 2020-02-19 0001626878 us-gaap:RetainedEarningsMember 2020-02-19 2020-02-19 0001626878 2018-12-31 0001626878 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001626878 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-12-31 0001626878 us-gaap:RetainedEarningsMember 2018-12-31 0001626878 us-gaap:AccountingStandardsUpdate201602Member srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-01-01 0001626878 2019-03-31 0001626878 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001626878 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-03-31 0001626878 us-gaap:RetainedEarningsMember 2019-03-31 0001626878 xbit:EquityDistributionAgreementMember 2019-06-30 0001626878 2019-12-31 0001626878 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001626878 xbit:ManufacturingEquipmentMember 2019-12-31 0001626878 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2019-12-31 0001626878 xbit:WinnebagoBuildingMember 2019-12-31 0001626878 srt:MaximumMember 2019-12-31 0001626878 srt:MinimumMember 2019-12-31 0001626878 srt:WeightedAverageMember 2019-12-31 0001626878 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001626878 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-12-31 0001626878 us-gaap:RetainedEarningsMember 2019-12-31 0001626878 2020-01-04 0001626878 srt:MaximumMember 2020-01-04 0001626878 srt:MinimumMember 2020-01-04 0001626878 2020-02-19 0001626878 2020-03-31 0001626878 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001626878 xbit:JanssenMember xbit:ClinicalTrialServiceRevenueMember 2020-03-31 0001626878 xbit:JanssenMember xbit:ManufacturingRevenueMember 2020-03-31 0001626878 xbit:ManufacturingEquipmentMember 2020-03-31 0001626878 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2020-03-31 0001626878 xbit:WinnebagoBuildingMember 2020-03-31 0001626878 srt:MaximumMember 2020-03-31 0001626878 srt:MinimumMember 2020-03-31 0001626878 srt:WeightedAverageMember 2020-03-31 0001626878 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001626878 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-03-31 0001626878 us-gaap:RetainedEarningsMember 2020-03-31 0001626878 2020-05-11

EX-101.SCH 6 xbit-20200331.xsd XBRL SCHEMA FILE 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Organization link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Revenue link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Common Stock link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Common Stock Options link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 2 - Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 4 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 6 - Common Stock Options (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 1 - Organization (Details Textual) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 2 - Significant Accounting Policies - Share-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 2 - Significant Accounting Policies - Stock Option Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 3 - Revenue (Details Textual) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 4 - Property and Equipment - Property and Equipment, Net (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 5 - Common Stock (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 6 - Common Stock Options (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 6 - Common Stock Options - Changes in Common Stock Options Issued (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 8 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 xbit-20200331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 xbit-20200331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 xbit-20200331_lab.xml XBRL LABEL FILE Document And Entity Information Fair Value Measurement, Policy [Policy Text Block] Dividend yield Other income (loss): Note To Financial Statement Details Textual Significant Accounting Policies Note 2 - Significant Accounting Policies Note 4 - Property and Equipment Risk-free interest rate Note 6 - Common Stock Options Segment Reporting, Policy [Policy Text Block] Note 7 - Net Income (Loss) Per Share Subsequent Events, Policy [Policy Text Block] Note 2 - Significant Accounting Policies - Share-based Compensation Expense (Details) Long-term liabilities: Note 2 - Significant Accounting Policies - Stock Option Valuation Assumptions (Details) Note 4 - Property and Equipment - Property and Equipment, Net (Details) Note 6 - Common Stock Options - Changes in Common Stock Options Issued (Details) Income Tax Disclosure [Text Block] Note 7 - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Notes To Financial Statements Foreign Currency Transactions and Translations Policy [Policy Text Block] Notes To Financial Statements [Abstract] us-gaap_ShareBasedCompensation Share-based compensation expense Expected volatility us-gaap_LiabilitiesCurrent Total current liabilities Expected life (Year) Earnings Per Share, Policy [Policy Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Operating expenses: Comprehensive Income, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] us-gaap_AssetsFairValueDisclosure Assets, Fair Value Disclosure Share-based Payment Arrangement, Option, Activity [Table Text Block] Foreign currency translation adjustment Research and Development Expense, Policy [Policy Text Block] Depreciation us-gaap_LiabilitiesFairValueDisclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) us-gaap_AssetsCurrent Total current assets Share-based Payment Arrangement [Policy Text Block] Stockholders' Equity Note Disclosure [Text Block] Weighted-average grant date fair value per share (in dollars per share) Income tax receivable Share repurchases of common stock and warrants, net The net cash inflow (outflow) from repurchase of common stock and warrants. Common stock, no par value, unlimited shares authorized, 28,852,927 and 41,519,633 shares outstanding at March 31, 2020 and December 31, 2019, respectively Measurement Frequency [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Options outstanding, exercise price (in dollars per share) Options outstanding, exercise price (in dollars per share) Fair Value, Recurring [Member] Common stock, shares authorized Forfeitures, exercise price (in dollars per share) Contract Liabilities us-gaap_CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share (in dollars per share) Common stock, no par value (in dollars per share) Common Stock, No Par Value (in dollars per share) Granted, exercise price (in dollars per share) Revenue from Contract with Customer [Policy Text Block] Exercised, exercise price (in dollars per share) Escrow receivable Represents the amount of escrow receivable. Accrued expenses Income taxes payable Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Weighted Average [Member] Accounts payable Product and Service [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Options outstanding (in shares) Options outstanding (in shares) Product and Service [Domain] Statistical Measurement [Axis] Collection of stock subscription receivable Amount of increase to additional paid-in capital (APIC) for collection of stock subscription receivable. Mobile Facility [Member] Information pertaining to mobile facility. Accrued purchases of property and equipment Equity Distribution Agreement [Member] Represents the information pertaining to the equity distribution agreement. xbit_ProceedsFromIssuanceOfCommonStockNet Proceeds from Issuance of Common Stock, Net The cash inflow from the additional capital contribution to the entity, net of issuance costs. Preferred stock, no par value, unlimited shares authorized, no shares outstanding Preferred stock, shares authorized us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Tender offer buyback Stock Issued During Period, Value, Tender Off Payback Represents the shares buyback equity impact amount . us-gaap_PolicyTextBlockAbstract Accounting Policies Preferred stock, no par value (in dollars per share) Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Revenue Revenue from Contract with Customer, Including Assessed Tax us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment Foreign exchange loss Customer [Axis] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) Customer [Domain] Current liabilities: us-gaap_Assets Total assets Supplemental Information: Cumulative Effect, Period of Adoption [Domain] xbit_PercentageOfOutstandingSharesRepurchased Percentage of Outstanding Shares Repurchased Represents the percentage of outstanding shares repurchased. us-gaap_ProceedsFromCustomers Proceeds from Customers Cumulative Effect, Period of Adoption [Axis] us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Cumulative Effect, Period of Adoption, Adjustment [Member] Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Operating activities us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Clinical Trial Service Revenue [Member] Represents information regarding clinical trial service revenue. Deferred cost of goods sold Represents the amount of deferred cost of goods sold as of the balance sheet date. Statement [Line Items] Manufacturing Revenue [Member] Represents information regarding revenue from manufacturing. Janssen [Member] Represents information regarding Janssen. Furniture and Fixtures [Member] us-gaap_NumberOfOperatingSegments Number of Operating Segments Accounts receivable xbit_IncreaseDecreaseInDeferredCostOfGoodsSold Deferred cost of goods sold Represents the amount of increase (decrease) in deferred cost of goods sold during the period. xbit_TransitionServicesAgreementMarkupPercentage Transition Services Agreement, Markup Percentage Represents the percentage markup under a transition services agreement. xbit_TransitionServicesAgreementNumberOfOngoingClinicalTrialsEnteredInto Transition Services Agreement, Number of Ongoing Clinical Trials Entered Into Represents the number of ongoing clinical trials entered into. xbit_ClinicalManufacturingAgreementQuarterlyPaymentsToBeReceived Clinical Manufacturing Agreement, Quarterly Payments to Be Received Represents the amount of each quarterly payment to be received under a clinical manufacturing agreement. Property, Plant and Equipment, Other Types [Member] Deferred tax asset Building [Member] xbit_StockRepurchaseProgramPurchasePricePerShare Stock Repurchase Program, Purchase Price Per Share (in dollars per share) Represents the purchase price per share under stock repurchase plan. Share-based Payment Arrangement [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] AOCI Attributable to Parent [Member] Shareholders’ equity: Property, Plant and Equipment, Policy [Policy Text Block] Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Total other income (loss) Long-Lived Tangible Asset [Domain] Award Type [Domain] Other income Current assets: Interest income Award Type [Axis] Net loss Net loss xbit_SubscriptionReceivable Subscription receivable The amount of subscription receivable. us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by (used in) financing activities Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Loss from operations Share-based Payment Arrangement, Option [Member] us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Effect of foreign exchange rate on cash and cash equivalents us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Net change in cash and cash equivalents us-gaap_GrossProfit Gross margin Cost of goods sold Cost of Goods and Services Sold, Total us-gaap_ContractWithCustomerLiability Contract with Customer, Liability, Total Property and equipment, net Property, Plant and Equipment, Net Accounting Standards Update 2016-02 [Member] Accounting Standards Update [Domain] Canada Revenue Agency [Member] Concentration Risk, Credit Risk, Policy [Policy Text Block] Accounting Standards Update [Axis] Investing activities Stock subscription receivable The monetary value of shares issued under the subscription during the period. Retained Earnings [Member] Earnings Per Share [Text Block] us-gaap_ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock Title of Individual [Domain] Title of Individual [Axis] us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Tax payable Issuance of common stock under stock option plan us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Common Stock Including Additional Paid in Capital [Member] Common Stock [Member] us-gaap_StockRepurchaseProgramAuthorizedAmount1 Stock Repurchase Program, Authorized Amount us-gaap_IncomeTaxExpenseBenefit Income Tax Expense (Benefit), Total Provision for income taxes Accrued expenses us-gaap_IncreaseDecreaseInAccruedLiabilities Equity Components [Axis] Equity Component [Domain] Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income taxes us-gaap_OperatingExpenses Total operating expenses General and administrative Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Vehicles [Member] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority [Axis] Income Tax Authority [Domain] Domestic Tax Authority [Member] us-gaap_AllocatedShareBasedCompensationExpense Share-based compensation expense xbit_StockRepurchasedDuringPeriodPricePerShare Stock Repurchased During Period, Price Per Share (in dollars per share) Represents the price per share for stock repurchased during the period. Office Equipment [Member] Equipment [Member] us-gaap_IncreaseDecreaseInDeferredLiabilities Deferred rent xbit_UnderwritersCommissionAttributableToIssuanceOfCommonStock Underwriter's Commission Attributable to Issuance of Common Stock Represents the amount of underwriter's commission related to the issuance of common stock. Revenue from Contract with Customer [Text Block] xbit_OtherRelatedFeeAttributableToIssuanceOfCommonStock Other Related Fee Attributable to Issuance of Common Stock Represents the amount of other related fee attributable to the issuance of common stock. EX-101.PRE 10 xbit-20200331_pre.xml XBRL PRESENTATION FILE EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.20.1

Note 2 - Significant Accounting Policies (Tables)
3 Months Ended

Mar. 31, 2020

Notes Tables

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

Three Months Ended

March 31,

2020 2019

Research and development $
533
$
295

General and administrative
2,144

275

Total share-based compensation expense
779

-

Research and development $
3,456
$
570

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Three Months Ended

March 31,

2020 2019

Dividend yield

-

-

Expected volatility
88%

-

91%

80%

-

82%

Risk-free interest rate
0.5%

-

1.87%

2.46%

-

2.64%

Expected life (in years)
6.25

-

10

5.75

-

10

Weighted-average grant date fair value per share

$12.08

$3.92

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 13 R14.htm IDEA: XBRL DOCUMENT v3.20.1

Note 7 - Net Income (Loss) Per Share
3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Earnings Per Share [Text Block]

7.

Net Income/Loss Per Share

The following summarizes the computation of basic and diluted net income/loss per share for the quarter ended
March 31, 2020
and
2019
(in thousands, except share and per share data):

Three Months Ended
March 31,

2020 2019

Net loss $
(14
) $
(5,864
)

Weighted-average number of common shares—basic and diluted
36,169,493

35,977,422

Net loss per share—basic and diluted $
(0.00
) $
(0.16
)

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 14 R10.htm IDEA: XBRL DOCUMENT v3.20.1

Note 3 - Revenue
3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

3.

Revenue

We received payment of
$4.5
million from Janssen based on billing schedules established in the contract on
December 30, 2019
for manufacturing in the
first
quarter of
2020.
Due to the coronavirus pandemic, the Company failed to fully complete the manufacture of drugs specified for the
March
purchase order due to supply disruptions for the syringes used to hold the manufactured compound. In addition, due to the pandemic, Janssen requested that we delay shipment of volumes for which we had completed manufacturing. We recognized revenue for those volumes held at Janssen’s request, as they are segregated for future delivery.
$1.5
million has been recorded as deferred revenue to a future period for the volumes that were
not
completed due to the syringe shortage until they are completed and delivered
. We received the syringe shipment in
April,
and currently anticipate fulfilling all production volumes and returning to normal manufacturing capabilities by the
third
quarter of
2020;
however, due to the uncertainty associated with the pandemic and related mitigation efforts, it is possible this assessment could change in future periods.

On
December 30, 2019,
the Company entered into a Transition Services Agreement with Janssen. Pursuant to the Transition Services Agreement, the company has agreed to continue operational management, on a fee-for-service basis, of
two
ongoing clinical trials related to bermekimab.
In consideration for all of the services to be provided, for each calendar quarter during the term of such agreement, Janssen shall pay the Company a fee for such quarter equal to all pass-through costs incurred by the Company during such calendar quarter, plus a markup of
30%.
At
March 31, 2020,
the Company has recorded
$7
million of gross revenue under this arrangement with the corresponding expense to clinical services cost of goods sold.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 15 R26.htm IDEA: XBRL DOCUMENT v3.20.1

Note 3 - Revenue (Details Textual)
$ in Thousands
3 Months Ended

Dec. 30, 2019

USD ($)

Mar. 31, 2020

USD ($)

Mar. 31, 2019

USD ($)

Cost of Goods and Services Sold, Total $ 9,674

Manufacturing Revenue [Member]

Cost of Goods and Services Sold, Total 2,166

Clinical Trial Service Revenue [Member]

Cost of Goods and Services Sold, Total 7,508

Janssen [Member] | Manufacturing Revenue [Member]

Proceeds from Customers $ 4,500

Contract with Customer, Liability, Total $ 1,500

Janssen [Member] | Clinical Trial Service Revenue [Member]

Transition Services Agreement, Number of Ongoing Clinical Trials Entered Into 2

Transition Services Agreement, Markup Percentage 30.00%

Janssen [Member] | Clinical Trial Service Revenue [Member] | Minimum [Member]

Cost of Goods and Services Sold, Total $ 7,500

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash receipts from customers during the current period which are usually for sales of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585
+ Details

Name: us-gaap_ProceedsFromCustomers

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the percentage markup under a transition services agreement.
+ References
No definition available.
+ Details

Name: xbit_TransitionServicesAgreementMarkupPercentage

Namespace Prefix: xbit_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the number of ongoing clinical trials entered into.
+ References
No definition available.
+ Details

Name: xbit_TransitionServicesAgreementNumberOfOngoingClinicalTrialsEnteredInto

Namespace Prefix: xbit_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=xbit_ManufacturingRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=xbit_ClinicalTrialServiceRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=xbit_JanssenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 16 R22.htm IDEA: XBRL DOCUMENT v3.20.1

Note 1 - Organization (Details Textual) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Mar. 31, 2019

Dec. 31, 2018

Cash and Cash Equivalents, at Carrying Value, Ending Balance $ 241,540 $ 714,594 $ 12,019 $ 15,823

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

ZIP 17 0001171843-20-003601-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-20-003601-xbrl.zip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end XML 18 R8.htm IDEA: XBRL DOCUMENT v3.20.1

Note 1 - Organization
3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1.

Organization

XBiotech Inc. (XBiotech or the Company) was incorporated in Canada on
March
22,

2005.
XBiotech USA, Inc., a wholly-owned subsidiary of the Company, was incorporated in Delaware, United States in
November
2007.
XBiotech Switzerland AG, a wholly-owned subsidiary of the Company, was incorporated in Zug, Switzerland in
August
2010.
XBiotech Japan K.K., a wholly-owned subsidiary of the Company, was incorporated in Tokyo, Japan in
March 2013.
XBiotech Germany GmbH, a wholly-owned subsidiary of the Company, was incorporated in Germany in
January 2014.
The Company’s headquarters are located in Austin, Texas.

Since its inception, XBiotech has focused on advancing technology to rapidly identify and clone antibodies from individuals that have resistance to disease. At the heart of the Company is a proprietary technical knowhow to translate natural human immunity into therapeutic product candidates.

In
2005,
the Company began to develop a new framework for commercial manufacturing, using technology that required less capital, fewer operators and provided greater flexibility than standard industry practices.

With the manufacturing capability to produce its True Human
™
antibody therapy, in
2010,
the Company began a clinical trial program. The
first
clinical trial program at MD Anderson Cancer Center began treating the sickest cancer patients irrespective of tumor type. Soon thereafter, the Company used the same antibody therapy in various clinical studies at treatment centers around the United States (U.S.) and abroad to investigate the antibody effect in patients that had vascular disease, leukemia, type
2
diabetes, psoriasis or acne.

The Company continues to be subject to a number of risks common to companies in similar stages of development. Principal among these risks are the uncertainties of technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors and protection of proprietary technology. All of these risks are likely to be exacerbated by the outbreak of the novel strain of coronavirus, SARS-CoV-
2
(“COVID-
19”
) and its ongoing impact, which has disrupted our business operations and will continue to do so. We cannot determine at this time the length or severity of these disruptions. The Company’s ability to fund its planned clinical operations, including completion of its planned trials, is expected to depend on the amount and timing of cash receipts from future collaboration or product sales and/or financing transactions. On
December 30, 2020,
the Company entered into a clinical manufacturing agreement and a clinical trial service agreement with Janssen Biotech Inc. The Company believes that its cash and cash equivalents of
$241.5
million at
March 31, 2020,
as well as revenue generated from the Janssen contracts will enable the Company to achieve several major inflection points, including potential new clinical studies with our lead product candidate. We expect to have sufficient cash through
one
year from the report issuance date.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R4.htm IDEA: XBRL DOCUMENT v3.20.1

Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Revenue $ 12,681 $ 0

Cost of goods sold 9,674

Gross margin 3,007

Operating expenses:

Research and development 1,155 4,527

General and administrative 4,023 1,278

Total operating expenses 5,178 5,805

Loss from operations (2,171) (5,805)

Other income (loss):

Interest income 1,898 78

Other income 9

Foreign exchange loss (93) (146)

Total other income (loss) 1,805 (59)

Loss before income taxes (366) (5,864)

Provision for income taxes 352 0

Net loss $ (14) $ (5,864)

Net loss per share—basic and diluted (in dollars per share) $ 0 $ (0.16)

Weighted-average number of common shares—basic and diluted (in shares) 36,169,493 35,977,422

Manufacturing Revenue [Member]

Revenue $ 3,000

Cost of goods sold 2,166

Clinical Trial Service Revenue [Member]

Revenue 9,681

Cost of goods sold $ 7,508

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 35
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(a),(b))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_InvestmentIncomeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income related to nonoperating activities, classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(7)(d))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=xbit_ManufacturingRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=xbit_ClinicalTrialServiceRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R27.htm IDEA: XBRL DOCUMENT v3.20.1

Note 4 - Property and Equipment - Property and Equipment, Net (Details) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Property, Plant and Equipment, Net $ 25,034 $ 25,171

Manufacturing Equipment [Member]

Property, Plant and Equipment, Net 3,420 3,492

Winnebago Building [Member]

Property, Plant and Equipment, Net 19,275 19,406

Property, Plant and Equipment, Other Types [Member]

Property, Plant and Equipment, Net $ 2,339 $ 2,273

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=xbit_ManufacturingEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=xbit_WinnebagoBuildingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R23.htm IDEA: XBRL DOCUMENT v3.20.1

Note 2 - Significant Accounting Policies (Details Textual)
$ in Thousands
3 Months Ended 15 Months Ended

Dec. 30, 2019

USD ($)

Mar. 31, 2020

USD ($)

Mar. 31, 2019

USD ($)

Mar. 31, 2020

USD ($)

Dec. 31, 2019

USD ($)

Jan. 01, 2019

USD ($)

Dec. 31, 2018

USD ($)

Cost of Goods and Services Sold, Total $ 9,674

Revenue from Contract with Customer, Including Assessed Tax 12,681 0

Impairment of Long-Lived Assets Held-for-use $ 0

Number of Operating Segments 1

Cumulative Effect of New Accounting Principle in Period of Adoption $ 347,082 36,983 $ 347,082 $ 755,631 $ 41,398

Retained Earnings [Member]

Cumulative Effect of New Accounting Principle in Period of Adoption 104,155 (243,564) $ 104,155 430,929 $ (237,700)

Accounting Standards Update 2016-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | Retained Earnings [Member]

Cumulative Effect of New Accounting Principle in Period of Adoption $ 0

Furniture and Fixtures [Member]

Property, Plant and Equipment, Useful Life (Year) 7 years

Office Equipment [Member]

Property, Plant and Equipment, Useful Life (Year) 5 years

Equipment [Member]

Property, Plant and Equipment, Useful Life (Year) 5 years

Vehicles [Member]

Property, Plant and Equipment, Useful Life (Year) 5 years

Mobile Facility [Member]

Property, Plant and Equipment, Useful Life (Year) 27 years 182 days

Building [Member]

Property, Plant and Equipment, Useful Life (Year) 39 years

Fair Value, Recurring [Member]

Assets, Fair Value Disclosure 0 $ 0 0

Financial and Nonfinancial Liabilities, Fair Value Disclosure 0 0 $ 0

Manufacturing Revenue [Member]

Cost of Goods and Services Sold, Total 2,166

Revenue from Contract with Customer, Including Assessed Tax 3,000

Clinical Trial Service Revenue [Member]

Cost of Goods and Services Sold, Total 7,508

Revenue from Contract with Customer, Including Assessed Tax 9,681

Janssen [Member] | Manufacturing Revenue [Member]

Clinical Manufacturing Agreement, Quarterly Payments to Be Received 4,500

Proceeds from Customers $ 4,500

Contract with Customer, Liability, Total $ 1,500 $ 1,500

Janssen [Member] | Clinical Trial Service Revenue [Member]

Transition Services Agreement, Number of Ongoing Clinical Trials Entered Into 2

Transition Services Agreement, Markup Percentage 30.00% 30.00%

Janssen [Member] | Clinical Trial Service Revenue [Member] | Minimum [Member]

Cost of Goods and Services Sold, Total $ 7,500

Revenue from Contract with Customer, Including Assessed Tax $ 9,700

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228
+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value of financial and nonfinancial obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_LiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash receipts from customers during the current period which are usually for sales of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585
+ Details

Name: us-gaap_ProceedsFromCustomers

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents the amount of each quarterly payment to be received under a clinical manufacturing agreement.
+ References
No definition available.
+ Details

Name: xbit_ClinicalManufacturingAgreementQuarterlyPaymentsToBeReceived

Namespace Prefix: xbit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the percentage markup under a transition services agreement.
+ References
No definition available.
+ Details

Name: xbit_TransitionServicesAgreementMarkupPercentage

Namespace Prefix: xbit_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the number of ongoing clinical trials entered into.
+ References
No definition available.
+ Details

Name: xbit_TransitionServicesAgreementNumberOfOngoingClinicalTrialsEnteredInto

Namespace Prefix: xbit_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=xbit_MobileFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=xbit_ManufacturingRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=xbit_ClinicalTrialServiceRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=xbit_JanssenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R5.htm IDEA: XBRL DOCUMENT v3.20.1

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Net loss $ (14) $ (5,864)

Foreign currency translation adjustment 90 138

Comprehensive loss $ (76) $ (5,726)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 23 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 24 R1.htm IDEA: XBRL DOCUMENT v3.20.1

Document And Entity Information - shares
3 Months Ended

Mar. 31, 2020

May 11, 2020

Document Information [Line Items]

Entity Registrant Name XBiotech Inc.

Entity Central Index Key 0001626878

Trading Symbol xbit

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Current Reporting Status Yes

Entity Emerging Growth Company false

Entity Small Business true

Entity Interactive Data Current Yes

Entity Common Stock, Shares Outstanding (in shares) 28,852,927

Entity Shell Company false

Document Type 10-Q

Document Period End Date Mar. 31, 2020

Document Fiscal Year Focus 2020

Document Fiscal Period Focus Q1

Amendment Flag false

Title of 12(b) Security Common Stock, no par value

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 25 R9.htm IDEA: XBRL DOCUMENT v3.20.1

Note 2 - Significant Accounting Policies
3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Significant Accounting Policies [Text Block]

2.

Significant Accounting Policies

Basis of Presentation

These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“US GAAP”). In the opinion of management, the accompanying consolidated financial statements reflect all adjustments (consisting only of normal recurring items) considered necessary to present fairly the Company’s financial position at
March 31, 2020
and
December 31, 2019,
the results of its operations and comprehensive loss for the
three
month periods ended
March 31, 2020
and
2019,
and the cash flows for the
three
month periods ended
March 31, 2020
and
2019.

Basis of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation.

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.

Revenue

Revenue from Janssen Agreements

The Company recognizes revenues from its Janssen Agreements as follows.

The Company entered into its clinical manufacturing and clinical trial services arrangements in connection with its sale of certain intellectual property on
December 30, 2019.
These contracts commenced
January 1, 2020.
While these agreements are
not
considered contracts with a customer based on the terms thereof, we are applying the revenue recognition guidance by analogy.

XBiotech is still in the research and development phase; however, the eventual output of the Company’s intended ordinary activities will be the licensing of intellectual property and/or sale of commercialized compounds for use in pharmaceutical treatment of disease,
not
the performance of manufacturing of development stage compounds or clinical trials for others. Although Janssen is
not
a customer, as these services are
not
the output of XBiotech’s ordinary activities, the Company evaluated the terms of the agreements and has analogized to Accounting Standards Codification, Topic
606,

Revenue from Contracts with Customers
(“ASC
606”
) for clinical manufacturing and clinical trial services revenue recognition.

Under ASC
606,
an entity recognizes revenue when (or as) its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC
606
(or for those analogized to it), the entity performs the following
five
steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the
five
-step model to contracts (including by analogy) when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the counterparty. At contract inception, once the contract is determined to be within the scope of or analogized to ASC
606,
we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Manufacturing Revenue

We have a Clinical Manufacturing Agreement that we account for by analogy to ASC
606,
under which we agreed to manufacture bermekimab for use by Janssen in clinical trials, in exchange for payments of
$4.5
million per quarter, paid in advance, for up to
two
years, though Janssen
may
terminate the contract for any reason with
60
-days’ notice. Quantities are estimated for the
two
-year period, but are only binding on the Company and Janssen for the next
four
months of each period, other than by the
60
-day notice termination. If, during any calendar quarter, the Company fails to deliver all of the Clinical Products ordered by Janssen, subject to our agreed upon capacity, the next quarter’s fee is reduced proportionately for the shortfall volume. Negative adjustments
may
also occur for delivered Clinical Products that do
not
meet quality specifications, though we expect to meet these standards.

We received payment of
$4.5
million from Janssen based on billing schedules established in the contract on
December 30, 2019
for manufacturing in the
first
quarter of
2020.
Due to the coronavirus pandemic, the Company failed to fully complete the manufacture of drugs specified for the
March
purchase order due to supply disruptions for the syringes used to hold the manufactured compound. In addition, due to the pandemic, Janssen requested that we delay shipment of volumes for which we had completed manufacturing. We recognized revenue for those volumes held at Janssen’s request, as they are segregated for future delivery.
$1.5
million has been recorded as deferred revenue to a future period for the volumes that were
not
completed due to the syringe shortage until they are completed and delivered
. We received the syringe shipment in
April,
and currently anticipate fulfilling all production volumes and returning to normal manufacturing capabilities by the
third
quarter of
2020;
however, due to the uncertainty associated with the pandemic and related mitigation efforts, it is possible this assessment could change in future periods.

Clinical Trial Service Revenue

On
December 30, 2019,
we entered into a Transition Services Agreement with Janssen. Pursuant to the Transition Services Agreement, the Company has agreed to continue operational management, on a fee-for-service basis, of
two
ongoing clinical trials related to bermekimab.
The arrangement
may
continue as long as the clinical trials are ongoing; however, Janssen
may
terminate the contract at any time with
thirty
days’ notice.

We have determined that XBiotech is a principal with regard to the single performance obligation for the series of clinical trial services. In consideration for all of the services to be provided, for each calendar quarter during the term of the Transition Services Agreement, Janssen pays the Company for all
third
party costs incurred (such as for
third
party clinical trial site costs) plus a markup of
30%,
which we recognize on a gross basis as the principal in the arrangement with Janssen. Those amounts relate directly to the Company’s efforts to provide clinical trial services in the respective month, and are allocated to that month’s services. As at
March 31, 2020,
the Company has recorded
$7.5
million Pass-Through Costs and
$9.7
million gross Clinical Trial Service Revenue.

Our clinical trial services were unaffected by the coronavirus pandemic during the
first
quarter of
2020.
However, the timelines for future clinical trial services could be extended in the future as a result of the pandemic, which could delay or otherwise adversely affect our revenue. Because our fees are directly related to
third
party costs of our vendors, our clinical trial service revenues in future periods are likely to be affected by our vendors’ ability to operate and the activities of trial candidates due to the effects of the pandemic and mitigating activities. Our
first
quarter results
may
not
be indicative of future revenues or costs associated with these clinical trials.

Research and Development Costs

All research and development costs are charged to expense as incurred. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract clinical trial research services, the costs of laboratory consumables, equipment and facilities, license fees and other external costs. Costs incurred to acquire licenses for intellectual property to be used in research and development activities with
no
alternative future use are expensed as incurred as research and development costs.

Share-Based Compensation

The Company accounts for its share-based compensation awards in accordance with ASC Topic
718,

Compensation-Stock Compensation
(“ASC
718”
). ASC
718
requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the board of directors for their services on the board of directors, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. To determine the fair value of its common stock, the Company uses the closing price of the Company’s common stock as reported by NASDAQ. For awards subject to service-based vesting conditions, the Company recognizes share-based compensation expense, equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur rather than on an estimated basis.

Share-based compensation expense recognized for the
three
months ended
March 31, 2020
and
2019
was included in the following line items on the Consolidated Statements of Operations (in thousands).

Three Months Ended

March 31,

2020 2019

Research and development $
533
$
295

General and administrative
2,144

275

Total share-based compensation expense
779

-

Research and development $
3,456
$
570

The fair value of each option is estimated on the date of grant using the Black-Scholes method with the following assumptions:

Three Months Ended

March 31,

2020 2019

Dividend yield

-

-

Expected volatility
88%

-

91%

80%

-

82%

Risk-free interest rate
0.5%

-

1.87%

2.46%

-

2.64%

Expected life (in years)
6.25

-

10

5.75

-

10

Weighted-average grant date fair value per share

$12.08

$3.92

Cash and Cash Equivalents

The Company considers highly liquid investments with a maturity of
three
months or less when purchased to be cash equivalents. Cash and cash equivalents consisted primarily of cash on deposit in U.S., German, Swiss, Japanese and Canadian banks. Cash and cash equivalents are stated at cost which approximates fair value.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any
one
financial institution. These amounts at times
may
exceed federally insured limits. The Company has
not
experienced any credit losses in such accounts and does
not
believe it is exposed to any significant credit risk on these funds. The Company has
no
off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.

Fair Value Measurements

The consolidated financial statements include financial instruments for which the fair market value of such instruments
may
differ from amounts reflected on a historical cost basis. Financial instruments of the Company consist of cash deposits, accounts and other receivables, accounts payable, and certain accrued liabilities. These financial instruments are held at cost, which generally approximates fair value due to their short-term nature.

The Company follows ASC Topic
820,

Fair Value Measurements and Disclosures
, which establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market date (observable inputs) and the Company’s own assumptions (unobservable inputs). The hierarchy consists of
three
levels:

• Level
1—Unadjusted
quoted prices in active markets for identical assets or liabilities.

• Level
2—Quoted
prices for similar assets and liabilities in active markets, quoted prices in markets that are
not
active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

• Level
3—Unobservable
inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

At
March 31, 2020
and
December 31, 2019,
the Company did
not

have any assets or liabilities that are measured at fair value on a recurring basis. The carrying amounts reflected in the balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values at
March 31, 2020
and
December 31, 2019,
due to their short-term nature.

Property and Equipment

Property and equipment, which consists of land, construction in process, furniture and fixtures, computers and office equipment, scientific equipment, leasehold improvements, vehicles and building are stated at cost and depreciated over the estimated useful lives of the assets, with the exception of land and construction in process which are
not
depreciated, using the straight line method. The useful lives are as follows:

•   Furniture and fixtures

7
years

•   Office equipment

5
years

•   Leasehold improvements

Shorter of asset’s useful life or remaining lease term

•   Scientific equipment

5
years

•   Vehicles
5
years

•   Mobile facility
27.5
years

•   Building

39
years

Costs of major additions and betterments are capitalized; maintenance and repairs, which do
not
improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized.

Impairment of Long-Lived Assets

The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic
360,

Property, Plant and Equipment
. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset
may
not
be recovered. Recoverability of these assets is assessed based on undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. The Company has
not
recognized any impairment through
March 31, 2020.

Income Taxes

Income taxes are recorded in accordance with ASC
740,

Accounting for Income Taxes
(“ASC
740”
), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than
not
that some or all of the deferred tax assets will
not
be realized.

The Company makes estimates and judgments in determining the need for a valuation allowance, including the estimation of its taxable income or loss for the quarter ended
March 31, 2020.
Realization of deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets certain deferred tax assets with a valuation allowance. The Company
may
in the future determine that certain deferred tax assets are more-likely-than-
not
be realized, in which case the Company will reduce its valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, the Company
may
recognize a benefit from income taxes in its statement of operations in that period.

ASC
740
clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position
may
be recognized when it is more likely than
not
that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods and disclosure. The Company’s policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of tax expense.

Foreign Currency Transactions

Certain transactions are denominated in a currency other than the Company’s functional currency of the U.S. dollar, and the Company generates assets and liabilities that are fixed in terms of the amount of foreign currency that will be received or paid. At each balance sheet date, the Company adjusts the assets and liabilities to reflect the current exchange rate, resulting in a translation gain or loss. Transaction gains and losses are also realized upon a settlement of a foreign currency transaction in determining net loss for the period in which the transaction is settled.

Comprehensive Income (Loss)

ASC Topic
220,

Comprehensive Income
, requires that all components of comprehensive income (loss), including net income (loss), be reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments.

Segment and Geographic Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company’s operations and manage its business as
one
operating segment. Substantially all of the Company’s operations are in the U.S. geographic segment.

Net Loss Per Share

Net income/loss per share (“EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net income/loss by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which include stock options, is computed using the treasury stock method.

Subsequent Events

The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in its consolidated financial statements. We have evaluated subsequent events through the date of filing this Form
10
-Q.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements

In
February 2016,
the FASB established Topic
842,
Leases, by issuing Accounting Standards Update (ASU)
No.

2016
-
02,
which supersedes ASC
840,
Leases, and requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic
842
was subsequently amended by ASU
No.

201801,
Land Easement Practical Expedient for Transition to Topic
842;
ASU
No.

2018
-
10,
Codification Improvements to Topic
842,
Leases; and ASU
No.

201811,
Targeted Improvements. Topic
842,
as amended (the "new lease standard") establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than
12
months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The effective date of the new guidance is for the Company’s
first
quarter of fiscal year
2019.
The FASB has approved an optional, alternative method to adopt the lease standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted the new standard effective
January 1, 2019,
using the alternative method. The Company did
not
have a cumulative adjustment impacting retained earnings. Adoption of the lease standard did
not
have a material impact on the Company’s consolidated financial statements.

In
June 2016,
the FASB issued ASU
No.

2016
-
13,
Financial Instruments—Credit Losses (Topic
326
): Measurement of Credit Losses on Financial Instruments. This ASU requires instruments measured at amortized cost to be presented at the net amount expected to be collected. Entities are also required to record allowances for available-for-sale debt securities rather than reduce the carrying amount. On
November 15, 2019,
the FASB delayed the effective date of the standard for certain small public companies and other private companies. As amended, the effective date of ASC Topic
326
was delayed until fiscal years beginning after
December 15, 2022
for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, as well as private companies and
not
-for-profit entities. The Company expects that the adoption will
not
have a material impact on its consolidated financial statements.

In
December 2019,
the FASB issued ASU
2019
-
12,
Income Taxes (Topic
740
): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic
740.
The amendments also improve consistent application of and simplify GAAP for other areas of Topic
740
by clarifying and amending existing guidance. The standard will become effective for interim and annual periods beginning after
December 15, 2020,
with early adoption permitted. We early adopted ASU
2019
-
12
during the quarter ended
March 31, 2020.
The adoption of ASU
2019
-
12
resulted in
no
material impact to the Company's financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 27 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 78 250 1 false 30 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://xbiotech.com/20200331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) Sheet http://xbiotech.com/20200331/role/statement-consolidated-balance-sheets-current-period-unaudited Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://xbiotech.com/20200331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://xbiotech.com/20200331/role/statement-consolidated-statements-of-operations-unaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://xbiotech.com/20200331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Shareholders' Equity (Unaudited) Sheet http://xbiotech.com/20200331/role/statement-consolidated-statements-of-shareholders-equity-unaudited Consolidated Statements of Shareholders' Equity (Unaudited) Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://xbiotech.com/20200331/role/statement-consolidated-statements-of-cash-flows-unaudited Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Organization Sheet http://xbiotech.com/20200331/role/statement-note-1-organization Note 1 - Organization Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Significant Accounting Policies Sheet http://xbiotech.com/20200331/role/statement-note-2-significant-accounting-policies Note 2 - Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Revenue Sheet http://xbiotech.com/20200331/role/statement-note-3-revenue Note 3 - Revenue Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Property and Equipment Sheet http://xbiotech.com/20200331/role/statement-note-4-property-and-equipment Note 4 - Property and Equipment Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Common Stock Sheet http://xbiotech.com/20200331/role/statement-note-5-common-stock Note 5 - Common Stock Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Common Stock Options Sheet http://xbiotech.com/20200331/role/statement-note-6-common-stock-options Note 6 - Common Stock Options Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Net Income (Loss) Per Share Sheet http://xbiotech.com/20200331/role/statement-note-7-net-income-loss-per-share Note 7 - Net Income (Loss) Per Share Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Income Taxes Sheet http://xbiotech.com/20200331/role/statement-note-8-income-taxes Note 8 - Income Taxes Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Subsequent Events Sheet http://xbiotech.com/20200331/role/statement-note-9-subsequent-events Note 9 - Subsequent Events Notes 16 false false R17.htm 016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://xbiotech.com/20200331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://xbiotech.com/20200331/role/statement-note-2-significant-accounting-policies 17 false false R18.htm 017 - Disclosure - Note 2 - Significant Accounting Policies (Tables) Sheet http://xbiotech.com/20200331/role/statement-note-2-significant-accounting-policies-tables Note 2 - Significant Accounting Policies (Tables) Tables http://xbiotech.com/20200331/role/statement-note-2-significant-accounting-policies 18 false false R19.htm 018 - Disclosure - Note 4 - Property and Equipment (Tables) Sheet http://xbiotech.com/20200331/role/statement-note-4-property-and-equipment-tables Note 4 - Property and Equipment (Tables) Tables http://xbiotech.com/20200331/role/statement-note-4-property-and-equipment 19 false false R20.htm 019 - Disclosure - Note 6 - Common Stock Options (Tables) Sheet http://xbiotech.com/20200331/role/statement-note-6-common-stock-options-tables Note 6 - Common Stock Options (Tables) Tables http://xbiotech.com/20200331/role/statement-note-6-common-stock-options 20 false false R21.htm 020 - Disclosure - Note 7 - Net Income (Loss) Per Share (Tables) Sheet http://xbiotech.com/20200331/role/statement-note-7-net-income-loss-per-share-tables Note 7 - Net Income (Loss) Per Share (Tables) Tables http://xbiotech.com/20200331/role/statement-note-7-net-income-loss-per-share 21 false false R22.htm 021 - Disclosure - Note 1 - Organization (Details Textual) Sheet http://xbiotech.com/20200331/role/statement-note-1-organization-details-textual Note 1 - Organization (Details Textual) Details http://xbiotech.com/20200331/role/statement-note-1-organization 22 false false R23.htm 022 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual) Sheet http://xbiotech.com/20200331/role/statement-note-2-significant-accounting-policies-details-textual Note 2 - Significant Accounting Policies (Details Textual) Details http://xbiotech.com/20200331/role/statement-note-2-significant-accounting-policies-tables 23 false false R24.htm 023 - Disclosure - Note 2 - Significant Accounting Policies - Share-based Compensation Expense (Details) Sheet http://xbiotech.com/20200331/role/statement-note-2-significant-accounting-policies-sharebased-compensation-expense-details Note 2 - Significant Accounting Policies - Share-based Compensation Expense (Details) Details 24 false false R25.htm 024 - Disclosure - Note 2 - Significant Accounting Policies - Stock Option Valuation Assumptions (Details) Sheet http://xbiotech.com/20200331/role/statement-note-2-significant-accounting-policies-stock-option-valuation-assumptions-details Note 2 - Significant Accounting Policies - Stock Option Valuation Assumptions (Details) Details 25 false false R26.htm 025 - Disclosure - Note 3 - Revenue (Details Textual) Sheet http://xbiotech.com/20200331/role/statement-note-3-revenue-details-textual Note 3 - Revenue (Details Textual) Details http://xbiotech.com/20200331/role/statement-note-3-revenue 26 false false R27.htm 026 - Disclosure - Note 4 - Property and Equipment - Property and Equipment, Net (Details) Sheet http://xbiotech.com/20200331/role/statement-note-4-property-and-equipment-property-and-equipment-net-details Note 4 - Property and Equipment - Property and Equipment, Net (Details) Details 27 false false R28.htm 027 - Disclosure - Note 5 - Common Stock (Details Textual) Sheet http://xbiotech.com/20200331/role/statement-note-5-common-stock-details-textual Note 5 - Common Stock (Details Textual) Details http://xbiotech.com/20200331/role/statement-note-5-common-stock 28 false false R29.htm 028 - Disclosure - Note 6 - Common Stock Options (Details Textual) Sheet http://xbiotech.com/20200331/role/statement-note-6-common-stock-options-details-textual Note 6 - Common Stock Options (Details Textual) Details http://xbiotech.com/20200331/role/statement-note-6-common-stock-options-tables 29 false false R30.htm 029 - Disclosure - Note 6 - Common Stock Options - Changes in Common Stock Options Issued (Details) Sheet http://xbiotech.com/20200331/role/statement-note-6-common-stock-options-changes-in-common-stock-options-issued-details Note 6 - Common Stock Options - Changes in Common Stock Options Issued (Details) Details 30 false false R31.htm 030 - Disclosure - Note 7 - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Sheet http://xbiotech.com/20200331/role/statement-note-7-net-income-loss-per-share-computation-of-basic-and-diluted-net-loss-per-share-details Note 7 - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Details http://xbiotech.com/20200331/role/statement-note-7-net-income-loss-per-share-tables 31 false false R32.htm 031 - Disclosure - Note 8 - Income Taxes (Details Textual) Sheet http://xbiotech.com/20200331/role/statement-note-8-income-taxes-details-textual Note 8 - Income Taxes (Details Textual) Details http://xbiotech.com/20200331/role/statement-note-8-income-taxes 32 false false All Reports Book All Reports xbit-20200331.xml xbit-20200331.xsd xbit-20200331_cal.xml xbit-20200331_def.xml xbit-20200331_lab.xml xbit-20200331_pre.xml http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2020-01-31 true true XML 28 R32.htm IDEA: XBRL DOCUMENT v3.20.1

Note 8 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
3 Months Ended

Jan. 01, 2020

Mar. 31, 2020

Mar. 31, 2019

Income Tax Expense (Benefit), Total $ (352) $ 0

Revenue from Contract with Customer, Including Assessed Tax $ 12,681 $ 0

Effective Income Tax Rate Reconciliation, Percent, Total 12.50%

Domestic Tax Authority [Member] | Canada Revenue Agency [Member]

Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent 27.00%

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R15.htm IDEA: XBRL DOCUMENT v3.20.1

Note 8 - Income Taxes
3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Income Tax Disclosure [Text Block]

8.

Income Taxes

The Company did
not
record a tax provision during the
three
months ended
March 31, 2019
due to the Company having
no
revenues or income prior to
December 2019.
During the
three
months ended
March
31,

2020,
the Company recorded an income tax benefit of
$352
thousand. The forecasted
2020
annual effective tax rate of
12.5%
has been applied to net income before income taxes for the
three
months ended
March 31, 2020.
Further adjustments have been made for the tax effect of discrete tax benefits of stock compensation realized during the current period, resulting in a
96.4%
effective tax rate for the
three
months ended
March
31,

2020.

The difference in the
27%
Canadian statutory tax rate and the annual forecasted effective tax rate is primarily a result of the jurisdictional mix of earnings and losses, valuation allowances, and permanently disallowed stock compensation expenses. The Company maintains a valuation allowance against all deferred tax assets in Switzerland, Germany and Japan and certain deferred tax assets in the US and Canada in the current and forecasted annual periods that we concluded are
not
more-likely-than-
not
to be realizable.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R11.htm IDEA: XBRL DOCUMENT v3.20.1

Note 4 - Property and Equipment
3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

4.

Property and Equipment

Property and equipment consisted of the following as of
March 31, 2020
and
December 31, 2019 (
in thousands):

March 31, 2020 December 31, 2019

Manufacturing equipment $
3,420
$
3,492

Winnebago building
19,275

19,406

Other fixed assets
2,339

2,273

Total property and equipment $
25,034
$
25,171

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.20.1

Note 4 - Property and Equipment (Tables)
3 Months Ended

Mar. 31, 2020

Notes Tables

Property, Plant and Equipment [Table Text Block]

March 31, 2020 December 31, 2019

Manufacturing equipment $
3,420
$
3,492

Winnebago building
19,275

19,406

Other fixed assets
2,339

2,273

Total property and equipment $
25,034
$
25,171

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R29.htm IDEA: XBRL DOCUMENT v3.20.1

Note 6 - Common Stock Options (Details Textual)
$ in Millions
3 Months Ended

Mar. 31, 2020

USD ($)

Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $ 13.6

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) 1 year 240 days

The Plan [Member] | Any One Person [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum 5.00%

The Plan [Member] | Share-based Payment Arrangement, Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 10 years

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=xbit_ThePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=xbit_AnyOnePersonMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 33 R25.htm IDEA: XBRL DOCUMENT v3.20.1

Note 2 - Significant Accounting Policies - Stock Option Valuation Assumptions (Details) - $ / shares
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Dividend yield

Weighted-average grant date fair value per share (in dollars per share) $ 12.08 $ 3.92

Minimum [Member]

Expected volatility 88.00% 80.00%

Risk-free interest rate 0.50% 2.46%

Expected life (Year) 6 years 91 days 5 years 273 days

Maximum [Member]

Expected volatility 91.00% 82.00%

Risk-free interest rate 1.87% 2.64%

Expected life (Year) 10 years 10 years

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R21.htm IDEA: XBRL DOCUMENT v3.20.1

Note 7 - Net Income (Loss) Per Share (Tables)
3 Months Ended

Mar. 31, 2020

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

Three Months Ended
March 31,

2020 2019

Net loss $
(14
) $
(5,864
)

Weighted-average number of common shares—basic and diluted
36,169,493

35,977,422

Net loss per share—basic and diluted $
(0.00
) $
(0.16
)

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R7.htm IDEA: XBRL DOCUMENT v3.20.1

Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Operating activities

Net loss $ (14) $ (5,864)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation 558 602

Share-based compensation expense 3,456 570

Account receivable (9,681)

Deferred cost of goods sold (1,703)

Income tax receivable (3,793)

Changes in operating assets and liabilities:

Prepaid expenses and other current assets 489 230

Accounts payable 3,470 99

Accrued expenses (2,815) (311)

Deferred revenue (3,000)

Deferred rent (3)

Tax payable (47,640)

Net cash used in operating activities (60,673) (4,677)

Investing activities

Purchase of property and equipment (389) (6)

Net cash used in investing activities (389) (6)

Financing activities

Share repurchases of common stock and warrants, net (420,000) 541

Issuance of common stock under stock option plan 7,918 200

Net cash provided by (used in) financing activities (412,082) 741

Effect of foreign exchange rate on cash and cash equivalents 90 138

Net change in cash and cash equivalents (473,054) (3,804)

Cash and cash equivalents, beginning of period 714,594 15,823

Cash and cash equivalents, end of period 241,540 12,019

Supplemental Information:

Accrued purchases of property and equipment 32 109

Subscription receivable $ 102

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInIncomeTaxesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the amount of increase (decrease) in deferred cost of goods sold during the period.
+ References
No definition available.
+ Details

Name: xbit_IncreaseDecreaseInDeferredCostOfGoodsSold

Namespace Prefix: xbit_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash inflow (outflow) from repurchase of common stock and warrants.
+ References
No definition available.
+ Details

Name: xbit_ProceedsFromPaymentsForRepurchaseOfCommonStockAndWarrantsNet

Namespace Prefix: xbit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of subscription receivable.
+ References
No definition available.
+ Details

Name: xbit_SubscriptionReceivable

Namespace Prefix: xbit_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 36 R3.htm IDEA: XBRL DOCUMENT v3.20.1

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares
$ / shares in Thousands
3 Months Ended 12 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Preferred stock, no par value (in dollars per share) $ 0 $ 0

Preferred stock, shares outstanding (in shares) 0 0

Preferred stock, shares authorized Unlimited Unlimited

Common stock, no par value (in dollars per share) $ 0 $ 0

Common stock, shares authorized Unlimited Unlimited

Common stock, shares outstanding (in shares) 28,852,927 41,519,633

X

- Definition
Face amount per share of no-par value common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockNoParValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is "Unlimited".
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorizedUnlimited

Namespace Prefix: us-gaap_

Data Type: us-types:authorizedUnlimitedItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockNoParValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicates that the number of nonredeemable preferred shares, or preferred stock redeemable solely at the option of the issuer, permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is "Unlimited".
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorizedUnlimited

Namespace Prefix: us-gaap_

Data Type: us-types:authorizedUnlimitedItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 37 R17.htm IDEA: XBRL DOCUMENT v3.20.1

Significant Accounting Policies (Policies)
3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation

These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“US GAAP”). In the opinion of management, the accompanying consolidated financial statements reflect all adjustments (consisting only of normal recurring items) considered necessary to present fairly the Company’s financial position at
March 31, 2020
and
December 31, 2019,
the results of its operations and comprehensive loss for the
three
month periods ended
March 31, 2020
and
2019,
and the cash flows for the
three
month periods ended
March 31, 2020
and
2019.

Consolidation, Policy [Policy Text Block]
Basis of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation.

Use of Estimates, Policy [Policy Text Block]
Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.

Revenue from Contract with Customer [Policy Text Block]
Revenue

Revenue from Janssen Agreements

The Company recognizes revenues from its Janssen Agreements as follows.

The Company entered into its clinical manufacturing and clinical trial services arrangements in connection with its sale of certain intellectual property on
December 30, 2019.
These contracts commenced
January 1, 2020.
While these agreements are
not
considered contracts with a customer based on the terms thereof, we are applying the revenue recognition guidance by analogy.

XBiotech is still in the research and development phase; however, the eventual output of the Company’s intended ordinary activities will be the licensing of intellectual property and/or sale of commercialized compounds for use in pharmaceutical treatment of disease,
not
the performance of manufacturing of development stage compounds or clinical trials for others. Although Janssen is
not
a customer, as these services are
not
the output of XBiotech’s ordinary activities, the Company evaluated the terms of the agreements and has analogized to Accounting Standards Codification, Topic
606,

Revenue from Contracts with Customers
(“ASC
606”
) for clinical manufacturing and clinical trial services revenue recognition.

Under ASC
606,
an entity recognizes revenue when (or as) its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC
606
(or for those analogized to it), the entity performs the following
five
steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the
five
-step model to contracts (including by analogy) when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the counterparty. At contract inception, once the contract is determined to be within the scope of or analogized to ASC
606,
we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Manufacturing Revenue

We have a Clinical Manufacturing Agreement that we account for by analogy to ASC
606,
under which we agreed to manufacture bermekimab for use by Janssen in clinical trials, in exchange for payments of
$4.5
million per quarter, paid in advance, for up to
two
years, though Janssen
may
terminate the contract for any reason with
60
-days’ notice. Quantities are estimated for the
two
-year period, but are only binding on the Company and Janssen for the next
four
months of each period, other than by the
60
-day notice termination. If, during any calendar quarter, the Company fails to deliver all of the Clinical Products ordered by Janssen, subject to our agreed upon capacity, the next quarter’s fee is reduced proportionately for the shortfall volume. Negative adjustments
may
also occur for delivered Clinical Products that do
not
meet quality specifications, though we expect to meet these standards.

We received payment of
$4.5
million from Janssen based on billing schedules established in the contract on
December 30, 2019
for manufacturing in the
first
quarter of
2020.
Due to the coronavirus pandemic, the Company failed to fully complete the manufacture of drugs specified for the
March
purchase order due to supply disruptions for the syringes used to hold the manufactured compound. In addition, due to the pandemic, Janssen requested that we delay shipment of volumes for which we had completed manufacturing. We recognized revenue for those volumes held at Janssen’s request, as they are segregated for future delivery.
$1.5
million has been recorded as deferred revenue to a future period for the volumes that were
not
completed due to the syringe shortage until they are completed and delivered
. We received the syringe shipment in
April,
and currently anticipate fulfilling all production volumes and returning to normal manufacturing capabilities by the
third
quarter of
2020;
however, due to the uncertainty associated with the pandemic and related mitigation efforts, it is possible this assessment could change in future periods.

Clinical Trial Service Revenue

On
December 30, 2019,
we entered into a Transition Services Agreement with Janssen. Pursuant to the Transition Services Agreement, the Company has agreed to continue operational management, on a fee-for-service basis, of
two
ongoing clinical trials related to bermekimab.
The arrangement
may
continue as long as the clinical trials are ongoing; however, Janssen
may
terminate the contract at any time with
thirty
days’ notice.

We have determined that XBiotech is a principal with regard to the single performance obligation for the series of clinical trial services. In consideration for all of the services to be provided, for each calendar quarter during the term of the Transition Services Agreement, Janssen pays the Company for all
third
party costs incurred (such as for
third
party clinical trial site costs) plus a markup of
30%,
which we recognize on a gross basis as the principal in the arrangement with Janssen. Those amounts relate directly to the Company’s efforts to provide clinical trial services in the respective month, and are allocated to that month’s services. As at
March 31, 2020,
the Company has recorded
$7.5
million Pass-Through Costs and
$9.7
million gross Clinical Trial Service Revenue.

Our clinical trial services were unaffected by the coronavirus pandemic during the
first
quarter of
2020.
However, the timelines for future clinical trial services could be extended in the future as a result of the pandemic, which could delay or otherwise adversely affect our revenue. Because our fees are directly related to
third
party costs of our vendors, our clinical trial service revenues in future periods are likely to be affected by our vendors’ ability to operate and the activities of trial candidates due to the effects of the pandemic and mitigating activities. Our
first
quarter results
may
not
be indicative of future revenues or costs associated with these clinical trials.

Research and Development Expense, Policy [Policy Text Block]
Research and Development Costs

All research and development costs are charged to expense as incurred. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract clinical trial research services, the costs of laboratory consumables, equipment and facilities, license fees and other external costs. Costs incurred to acquire licenses for intellectual property to be used in research and development activities with
no
alternative future use are expensed as incurred as research and development costs.

Share-based Payment Arrangement [Policy Text Block]
Share-Based Compensation

The Company accounts for its share-based compensation awards in accordance with ASC Topic
718,

Compensation-Stock Compensation
(“ASC
718”
). ASC
718
requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the board of directors for their services on the board of directors, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. To determine the fair value of its common stock, the Company uses the closing price of the Company’s common stock as reported by NASDAQ. For awards subject to service-based vesting conditions, the Company recognizes share-based compensation expense, equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur rather than on an estimated basis.

Share-based compensation expense recognized for the
three
months ended
March 31, 2020
and
2019
was included in the following line items on the Consolidated Statements of Operations (in thousands).

Three Months Ended

March 31,

2020 2019

Research and development $
533
$
295

General and administrative
2,144

275

Total share-based compensation expense
779

-

Research and development $
3,456
$
570

The fair value of each option is estimated on the date of grant using the Black-Scholes method with the following assumptions:

Three Months Ended

March 31,

2020 2019

Dividend yield

-

-

Expected volatility
88%

-

91%

80%

-

82%

Risk-free interest rate
0.5%

-

1.87%

2.46%

-

2.64%

Expected life (in years)
6.25

-

10

5.75

-

10

Weighted-average grant date fair value per share

$12.08

$3.92

Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents

The Company considers highly liquid investments with a maturity of
three
months or less when purchased to be cash equivalents. Cash and cash equivalents consisted primarily of cash on deposit in U.S., German, Swiss, Japanese and Canadian banks. Cash and cash equivalents are stated at cost which approximates fair value.

Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentrations of Credit Risk

Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any
one
financial institution. These amounts at times
may
exceed federally insured limits. The Company has
not
experienced any credit losses in such accounts and does
not
believe it is exposed to any significant credit risk on these funds. The Company has
no
off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.

Fair Value Measurement, Policy [Policy Text Block]
Fair Value Measurements

The consolidated financial statements include financial instruments for which the fair market value of such instruments
may
differ from amounts reflected on a historical cost basis. Financial instruments of the Company consist of cash deposits, accounts and other receivables, accounts payable, and certain accrued liabilities. These financial instruments are held at cost, which generally approximates fair value due to their short-term nature.

The Company follows ASC Topic
820,

Fair Value Measurements and Disclosures
, which establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market date (observable inputs) and the Company’s own assumptions (unobservable inputs). The hierarchy consists of
three
levels:

• Level
1—Unadjusted
quoted prices in active markets for identical assets or liabilities.

• Level
2—Quoted
prices for similar assets and liabilities in active markets, quoted prices in markets that are
not
active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

• Level
3—Unobservable
inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

At
March 31, 2020
and
December 31, 2019,
the Company did
not
have any assets or liabilities that are measured at fair value on a recurring basis. The carrying amounts reflected in the balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values at
March 31, 2020
and
December 31, 2019,
due to their short-term nature.

Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment

Property and equipment, which consists of land, construction in process, furniture and fixtures, computers and office equipment, scientific equipment, leasehold improvements, vehicles and building are stated at cost and depreciated over the estimated useful lives of the assets, with the exception of land and construction in process which are
not
depreciated, using the straight line method. The useful lives are as follows:

•   Furniture and fixtures

7
years

•   Office equipment

5
years

•   Leasehold improvements

Shorter of asset’s useful life or remaining lease term

•   Scientific equipment

5
years

•   Vehicles
5
years

•   Mobile facility
27.5
years

•   Building

39
years

Costs of major additions and betterments are capitalized; maintenance and repairs, which do
not
improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Impairment of Long-Lived Assets

The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic
360,

Property, Plant and Equipment
. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset
may
not
be recovered. Recoverability of these assets is assessed based on undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. The Company has
not
recognized any impairment through
March 31, 2020.

Income Tax, Policy [Policy Text Block]
Income Taxes

Income taxes are recorded in accordance with ASC
740,

Accounting for Income Taxes
(“ASC
740”
), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than
not
that some or all of the deferred tax assets will
not
be realized.

The Company makes estimates and judgments in determining the need for a valuation allowance, including the estimation of its taxable income or loss for the quarter ended
March 31, 2020.
Realization of deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets certain deferred tax assets with a valuation allowance. The Company
may
in the future determine that certain deferred tax assets are more-likely-than-
not
be realized, in which case the Company will reduce its valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, the Company
may
recognize a benefit from income taxes in its statement of operations in that period.

ASC
740
clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position
may
be recognized when it is more likely than
not
that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods and disclosure. The Company’s policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of tax expense.

Foreign Currency Transactions and Translations Policy [Policy Text Block]
Foreign Currency Transactions

Certain transactions are denominated in a currency other than the Company’s functional currency of the U.S. dollar, and the Company generates assets and liabilities that are fixed in terms of the amount of foreign currency that will be received or paid. At each balance sheet date, the Company adjusts the assets and liabilities to reflect the current exchange rate, resulting in a translation gain or loss. Transaction gains and losses are also realized upon a settlement of a foreign currency transaction in determining net loss for the period in which the transaction is settled.

Comprehensive Income, Policy [Policy Text Block]
Comprehensive Income (Loss)

ASC Topic
220,

Comprehensive Income
, requires that all components of comprehensive income (loss), including net income (loss), be reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments.

Segment Reporting, Policy [Policy Text Block]
Segment and Geographic Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company’s operations and manage its business as
one
operating segment. Substantially all of the Company’s operations are in the U.S. geographic segment.

Earnings Per Share, Policy [Policy Text Block]
Net Loss Per Share

Net income/loss per share (“EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net income/loss by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which include stock options, is computed using the treasury stock method.

Subsequent Events, Policy [Policy Text Block]
Subsequent Events

The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in its consolidated financial statements. We have evaluated subsequent events through the date of filing this Form
10
-Q.

New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements

In
February 2016,
the FASB established Topic
842,
Leases, by issuing Accounting Standards Update (ASU)
No.

2016
-
02,
which supersedes ASC
840,
Leases, and requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic
842
was subsequently amended by ASU
No.

201801,
Land Easement Practical Expedient for Transition to Topic
842;
ASU
No.

2018
-
10,
Codification Improvements to Topic
842,
Leases; and ASU
No.

201811,
Targeted Improvements. Topic
842,
as amended (the "new lease standard") establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than
12
months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The effective date of the new guidance is for the Company’s
first
quarter of fiscal year
2019.
The FASB has approved an optional, alternative method to adopt the lease standard by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted the new standard effective
January 1, 2019,
using the alternative method. The Company did
not
have a cumulative adjustment impacting retained earnings. Adoption of the lease standard did
not
have a material impact on the Company’s consolidated financial statements.

In
June 2016,
the FASB issued ASU
No.

2016
-
13,
Financial Instruments—Credit Losses (Topic
326
): Measurement of Credit Losses on Financial Instruments. This ASU requires instruments measured at amortized cost to be presented at the net amount expected to be collected. Entities are also required to record allowances for available-for-sale debt securities rather than reduce the carrying amount. On
November 15, 2019,
the FASB delayed the effective date of the standard for certain small public companies and other private companies. As amended, the effective date of ASC Topic
326
was delayed until fiscal years beginning after
December 15, 2022
for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, as well as private companies and
not
-for-profit entities. The Company expects that the adoption will
not
have a material impact on its consolidated financial statements.

In
December 2019,
the FASB issued ASU
2019
-
12,
Income Taxes (Topic
740
): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic
740.
The amendments also improve consistent application of and simplify GAAP for other areas of Topic
740
by clarifying and amending existing guidance. The standard will become effective for interim and annual periods beginning after
December 15, 2020,
with early adoption permitted. We early adopted ASU
2019
-
12
during the quarter ended
March 31, 2020.
The adoption of ASU
2019
-
12
resulted in
no
material impact to the Company's financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-URI http://asc.fasb.org/topic&trid=2175825

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue from contract with customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599
+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reporting subsequent events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_SubsequentEventsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R13.htm IDEA: XBRL DOCUMENT v3.20.1

Note 6 - Common Stock Options
3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

6.

Common Stock Options

On
November
11,

2005
and
April 1, 2015,
the board of directors of the Company adopted stock option plans (“the Plans”) pursuant to which the Company
may
grant incentive stock options to directors, officers, employees or consultants of the Company or an affiliate or other persons as the Compensation Committee
may
approve.

All options are non-transferable and
may
be exercised only by the participant, or in the event of the death of the participant, a legal representative until the earlier of the options’ expiry date or the
first
anniversary of the participant’s death, or such other date as
may
be specified by the Compensation Committee.

The term of the options is at the discretion of the Compensation Committee, but
may
not
exceed
10
years from the grant date. The options expire on the earlier of the expiration date or the date
three
months following the day on which the participant ceases to be an officer or employee of or consultant to the Company, or in the event of the termination of the participant with cause, the date of such termination. Options held by non-employee Directors have an exercise period coterminous with the term of the options.

The number of common shares reserved for issuance to any
one
person pursuant to the Plan adopted in
2005

may
not,
in aggregate, exceed
5%
of the total number of outstanding common shares. The exercise price per common share under each option is the fair market value of such shares at the time of the grant. Upon stock option exercise, the Company issues new shares of common stock.

A summary of changes in common stock options issued under the Plans is as follows:

Options Exercise Price Weighted-Average
Exercise Price

Options outstanding at December 31, 2019
6,965,730

$2.71

-

$21.99

6.09

Granted
50,500

8.89

-

21.8

15.40

Exercised
(1,333,294
)
2.94

-

19.09

5.94

Forfeitures
(12,167
)
4.95

-

10.36

8.13

Options outstanding at March 31, 2020
5,670,769

$2.71

-

$21.99

6.17

As of
March 31, 2020,
there was approximately
$13.6
million of unrecognized compensation cost, related to stock options granted under the Plans which will be amortized to stock compensation expense over the next
1.66
years.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R30.htm IDEA: XBRL DOCUMENT v3.20.1

Note 6 - Common Stock Options - Changes in Common Stock Options Issued (Details) - $ / shares
3 Months Ended 12 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Options outstanding (in shares) 6,965,730

Granted (in shares) 50,500

Exercised (in shares) (1,333,294) (771,000)

Forfeitures (in shares) (12,167)

Options outstanding (in shares) 5,670,769 6,965,730

Minimum [Member]

Options outstanding, exercise price (in dollars per share) $ 2.71

Granted, exercise price (in dollars per share) 8.89

Exercised, exercise price (in dollars per share) 2.94

Forfeitures, exercise price (in dollars per share) 4.95

Options outstanding, exercise price (in dollars per share) 2.71 $ 2.71

Maximum [Member]

Options outstanding, exercise price (in dollars per share) 21.99

Granted, exercise price (in dollars per share) 21.80

Exercised, exercise price (in dollars per share) 19.09

Forfeitures, exercise price (in dollars per share) 10.36

Options outstanding, exercise price (in dollars per share) 21.99 21.99

Weighted Average [Member]

Options outstanding, exercise price (in dollars per share) 6.09

Granted, exercise price (in dollars per share) 15.40

Exercised, exercise price (in dollars per share) 5.94

Forfeitures, exercise price (in dollars per share) 8.13

Options outstanding, exercise price (in dollars per share) $ 6.17 $ 6.09

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_WeightedAverageMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R16.htm IDEA: XBRL DOCUMENT v3.20.1

Note 9 - Subsequent Events
3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Subsequent Events [Text Block]

9.

Subsequent Events

The ongoing COVID-
19
pandemic is disrupting our business operations, which we expect to continue throughout the remainder of
2020
and possibly beyond. We have experienced actual disruption to our supply chain regarding our ability to obtain syringes, and we have experienced or
may
experience difficulty obtaining masks, gloves and stoppers for vials, all of which are required in our manufacturing and/or clinical and drug discovery operations. Disruptions to clinical activities have already impacted our contractual arrangements with Janssen, causing Janssen to reduce its drug manufacturing orders under the clinical manufacturing agreement. Although we concluded that COVID-
19
did
not
result in material adverse impacts on the Company’s results of operations and financial position at
March 31, 2020,
if supply disruptions and purchase reductions continue, our clinical manufacturing revenue will be, and our clinical trial service revenue could be, adversely impacted. In addition, stay-at-home orders and social distancing restrictions imposed by national, state and local governments have required adjustments to staffing levels and
may
impact the willingness of employees to work in laboratory, manufacturing and clinical settings, even after these orders and restrictions are relaxed or allowed to expire. Ongoing restrictions and other disruptions related to COVID-
19
could delay our efforts to identify, manufacture, enter into clinical studies, seek regulatory approvals or otherwise commercialize any product candidates.

On
April 3, 2020,
the Company announced the collaboration with BioBridge Global to participate in a U.S. Food and Drug Administration (FDA) investigational program
for U.S. blood centers to begin collecting and distributing convalescent plasma from individuals who have recovered from COVID-
19.
The Company intends to use the blood samples to develop a candidate True Human™ antibody therapy for the disease.

On
April 14, 2020,
the Company announced that a novel antibody it has discovered that neutralizes interleukin-
1
alpha (IL-
1⍺
) has now been advanced as a product candidate for clinical and commercial development. With the discovery, the Company is on schedule to reenter the clinic trials with a new anti-IL-
1⍺
therapy in
2021.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R12.htm IDEA: XBRL DOCUMENT v3.20.1

Note 5 - Common Stock
3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

5.

Common Stock

Pursuant to its Articles, the Company has an unlimited number of shares available for issuance with
no
par value.

During
June 2019,
under the Common Shares Purchase Agreement with Piper Jaffray & Co., the Company sold
4.8
million shares of common stock at a price
$8.25
per share for total net proceeds of
$37.5
million, including the capitalized underwriter’s commission of
$2.3
million and other related fees of
$0.2
million.

From
January
through
December 2019,
771
thousand shares of common stock were issued upon the exercise of stock options at a price of
$2.50
to
$15.00
per share for total proceeds of
$3.8
million.

On
January 4, 2020,
XBiotech announced that it had commenced a “modified Dutch auction” tender offer to purchase up to
$420,000,000
of its common shares, or such lesser number of common shares as are properly tendered and
not
properly withdrawn, at a price
not
less than
$30.00
nor greater than
$33.00
per common share, to the seller in cash. The tender offer expired on
February 12, 2020.

On
February 19, 2020,
the Company announced the final results of its “modified Dutch Auction” tender offer. The Company accepted for purchase
14,000,000
shares of its common stock,
$0.01
par value per share, at a price of
$30
per share, for an aggregate cost of approximately
$420
million, excluding fees and expenses related to the tender offer. These shares represented approximately
32.67
percent of the shares outstanding.
$6.66
per share or total of
$93.24
million of these share repurchases have been classified to reduce common stock and
$23.34
per share or total of
$326.76
million of these share repurchases have been classified to reduce retained earnings in the accompanying consolidated balance sheet as of
March 31, 2020.

From
January
through
March 2020,
1.3
million shares of common stock were issued upon the exercise of stock options at a price of
$2.94
to
$19.09
per share for total proceeds of
$7.9
million.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R31.htm IDEA: XBRL DOCUMENT v3.20.1

Note 7 - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Net loss $ (14) $ (5,864)

Weighted-average number of common shares—basic and diluted (in shares) 36,169,493 35,977,422

Net loss per share—basic and diluted (in dollars per share) $ 0 $ (0.16)

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 44 R24.htm IDEA: XBRL DOCUMENT v3.20.1

Note 2 - Significant Accounting Policies - Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Share-based compensation expense $ 779

Share-based compensation expense 3,456 570

Research and Development Expense [Member]

Share-based compensation expense 533 295

General and Administrative Expense [Member]

Share-based compensation expense $ 2,144 $ 275

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R20.htm IDEA: XBRL DOCUMENT v3.20.1

Note 6 - Common Stock Options (Tables)
3 Months Ended

Mar. 31, 2020

Notes Tables

Share-based Payment Arrangement, Option, Activity [Table Text Block]

Options Exercise Price Weighted-Average
Exercise Price

Options outstanding at December 31, 2019
6,965,730

$2.71

-

$21.99

6.09

Granted
50,500

8.89

-

21.8

15.40

Exercised
(1,333,294
)
2.94

-

19.09

5.94

Forfeitures
(12,167
)
4.95

-

10.36

8.13

Options outstanding at March 31, 2020
5,670,769

$2.71

-

$21.99

6.17

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R28.htm IDEA: XBRL DOCUMENT v3.20.1

Note 5 - Common Stock (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended

Feb. 19, 2020

Jun. 30, 2019

Mar. 31, 2020

Dec. 31, 2019

Jan. 04, 2020

Common Stock, No Par Value (in dollars per share) $ 0 $ 0

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) 1,333,294 771,000

Proceeds from Issuance of Common Stock $ 7,900,000 $ 3,800,000

Stock Repurchase Program, Authorized Amount $ 420,000,000

Stock Repurchased During Period, Shares (in shares) 14,000,000

Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.01

Stock Repurchased During Period, Price Per Share (in dollars per share) $ 30

Stock Repurchased During Period, Value $ 420,000,000

Percentage of Outstanding Shares Repurchased 32.67%

Stock Issued During Period, Value, Tender Off Payback (420,000,000)

Common Stock [Member]

Stock Repurchased During Period, Price Per Share (in dollars per share) $ 6.66

Stock Issued During Period, Value, Tender Off Payback $ 93,240,000

Retained Earnings [Member]

Stock Repurchased During Period, Price Per Share (in dollars per share) $ 23.34

Stock Issued During Period, Value, Tender Off Payback $ (326,760,000) $ (326,760,000)

Minimum [Member]

Shares Issued, Price Per Share (in dollars per share) $ 2.94 $ 2.50

Stock Repurchase Program, Purchase Price Per Share (in dollars per share) $ 30

Maximum [Member]

Shares Issued, Price Per Share (in dollars per share) $ 19.09 $ 15

Stock Repurchase Program, Purchase Price Per Share (in dollars per share) $ 33

Equity Distribution Agreement [Member]

Stock Issued During Period, Shares, New Issues (in shares) 4,800,000

Shares Issued, Price Per Share (in dollars per share) $ 8.25

Proceeds from Issuance of Common Stock, Net $ 37,500,000

Underwriter's Commission Attributable to Issuance of Common Stock 2,300,000

Other Related Fee Attributable to Issuance of Common Stock $ 200,000

X

- Definition
Face amount per share of no-par value common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockNoParValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of stock repurchase plan authorized.
+ References
No definition available.
+ Details

Name: us-gaap_StockRepurchaseProgramAuthorizedAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockRepurchasedDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockRepurchasedDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the amount of other related fee attributable to the issuance of common stock.
+ References
No definition available.
+ Details

Name: xbit_OtherRelatedFeeAttributableToIssuanceOfCommonStock

Namespace Prefix: xbit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the percentage of outstanding shares repurchased.
+ References
No definition available.
+ Details

Name: xbit_PercentageOfOutstandingSharesRepurchased

Namespace Prefix: xbit_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity, net of issuance costs.
+ References
No definition available.
+ Details

Name: xbit_ProceedsFromIssuanceOfCommonStockNet

Namespace Prefix: xbit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the shares buyback equity impact amount .
+ References
No definition available.
+ Details

Name: xbit_SharesBuybackEquityImpactAmount

Namespace Prefix: xbit_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the purchase price per share under stock repurchase plan.
+ References
No definition available.
+ Details

Name: xbit_StockRepurchaseProgramPurchasePricePerShare

Namespace Prefix: xbit_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the price per share for stock repurchased during the period.
+ References
No definition available.
+ Details

Name: xbit_StockRepurchasedDuringPeriodPricePerShare

Namespace Prefix: xbit_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the amount of underwriter's commission related to the issuance of common stock.
+ References
No definition available.
+ Details

Name: xbit_UnderwritersCommissionAttributableToIssuanceOfCommonStock

Namespace Prefix: xbit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=xbit_EquityDistributionAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R6.htm IDEA: XBRL DOCUMENT v3.20.1

Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands

Common Stock Including Additional Paid in Capital [Member]

AOCI Attributable to Parent [Member]

Retained Earnings [Member]

Total

Balance (in shares) at Dec. 31, 2018 35,900,000

Balance at Dec. 31, 2018 $ 279,353 $ (255) $ (237,700) $ 41,398

Net loss (5,864) (5,864)

Foreign currency translation adjustment 138 138

Issuance of common stock under stock option plan (in shares) 190,000

Issuance of common stock under stock option plan $ 643 643

Share-based compensation expense 570 570

Stock subscription receivable (102) (102)

Collection of stock subscription receivable $ 200 200

Balance (in shares) at Mar. 31, 2019 36,090,000

Balance at Mar. 31, 2019 $ 280,664 (117) (243,564) 36,983

Balance (in shares) at Dec. 31, 2019 41,519

Balance at Dec. 31, 2019 $ 324,808 (106) 430,929 755,631

Net loss (14) (14)

Tender offer buyback (in shares) (14,000)

Tender offer buyback $ (93,240) (326,760) (420,000)

Foreign currency translation adjustment 90 90

Issuance of common stock under stock option plan (in shares) 1,334

Issuance of common stock under stock option plan $ 7,918 7,918

Share-based compensation expense $ 3,456 3,456

Balance (in shares) at Mar. 31, 2020 28,853

Balance at Mar. 31, 2020 $ 242,942 $ (16) $ 104,155 $ 347,082

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockRepurchasedDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase to additional paid-in capital (APIC) for collection of stock subscription receivable.
+ References
No definition available.
+ Details

Name: xbit_AdjustmentsToAdditionalPaidInCapitalCollectionOfStockSubscriptionReceivable

Namespace Prefix: xbit_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The monetary value of shares issued under the subscription during the period.
+ References
No definition available.
+ Details

Name: xbit_CommonStockShareSubscribedValueIssuance

Namespace Prefix: xbit_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the shares buyback equity impact amount .
+ References
No definition available.
+ Details

Name: xbit_SharesBuybackEquityImpactAmount

Namespace Prefix: xbit_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 48 R2.htm IDEA: XBRL DOCUMENT v3.20.1

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Current assets:

Cash and cash equivalents $ 241,540 $ 714,594

Accounts receivable 9,681

Deferred cost of goods sold 1,703

Income tax receivable 3,793

Prepaid expenses and other current assets 1,179 1,669

Total current assets 257,896 716,263

Property and equipment, net 25,034 25,171

Escrow receivable 75,000 75,000

Deferred tax asset 443 443

Total assets 358,373 816,877

Current liabilities:

Accounts payable 5,649 2,149

Accrued expenses 1,371 4,180

Contract Liabilities 4,500

Deferred revenue 1,500

Income taxes payable 1,715 49,361

Total current liabilities 10,235 60,190

Long-term liabilities:

Deferred rent

Income tax payable - non-current 1,056 1,056

Total liabilities 11,291 61,246

Shareholders’ equity:

Preferred stock, no par value, unlimited shares authorized, no shares outstanding 0 0

Common stock, no par value, unlimited shares authorized, 28,852,927 and 41,519,633 shares outstanding at March 31, 2020 and December 31, 2019, respectively 242,942 324,808

Accumulated other comprehensive loss (16) (106)

Retained earnings 104,156 430,929

Total shareholders’ equity 347,082 755,631

Total liabilities and shareholders’ equity $ 358,373 $ 816,877

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15)(b)(1))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(1))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedIncomeTaxesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15)(b)(1))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(1))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedIncomeTaxesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598
+ Details

Name: us-gaap_DeferredIncomeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318
+ Details

Name: us-gaap_DeferredIncomeTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.26(c))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 25
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121549951&loc=d3e39927-112707
+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.5(c))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10)
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3(a)(4))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_IncomeTaxesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the amount of deferred cost of goods sold as of the balance sheet date.
+ References
No definition available.
+ Details

Name: xbit_DeferredCostOfGoodsSold

Namespace Prefix: xbit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the amount of escrow receivable.
+ References
No definition available.
+ Details

Name: xbit_EscrowReceivable

Namespace Prefix: xbit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

Note 3 - Revenue (Details Textual) $ in Thousands		3 Months Ended
Note 3 - Revenue (Details Textual) $ in Thousands	Dec. 30, 2019 USD ($)	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)
Cost of Goods and Services Sold, Total		$ 9,674
Manufacturing Revenue [Member]
Cost of Goods and Services Sold, Total		2,166
Clinical Trial Service Revenue [Member]
Cost of Goods and Services Sold, Total		7,508
Janssen [Member] \| Manufacturing Revenue [Member]
Proceeds from Customers	$ 4,500
Contract with Customer, Liability, Total		$ 1,500
Janssen [Member] \| Clinical Trial Service Revenue [Member]
Transition Services Agreement, Number of Ongoing Clinical Trials Entered Into	2
Transition Services Agreement, Markup Percentage		30.00%
Janssen [Member] \| Clinical Trial Service Revenue [Member] \| Minimum [Member]
Cost of Goods and Services Sold, Total		$ 7,500

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue	$ 12,681	$ 0
Cost of goods sold	9,674
Gross margin	3,007
Operating expenses:
Research and development	1,155	4,527
General and administrative	4,023	1,278
Total operating expenses	5,178	5,805
Loss from operations	(2,171)	(5,805)
Other income (loss):
Interest income	1,898	78
Other income		9
Foreign exchange loss	(93)	(146)
Total other income (loss)	1,805	(59)
Loss before income taxes	(366)	(5,864)
Provision for income taxes	352	0
Net loss	$ (14)	$ (5,864)
Net loss per share—basic and diluted (in dollars per share)	$ 0	$ (0.16)
Weighted-average number of common shares—basic and diluted (in shares)	36,169,493	35,977,422
Manufacturing Revenue [Member]
Revenue	$ 3,000
Cost of goods sold	2,166
Clinical Trial Service Revenue [Member]
Revenue	9,681
Cost of goods sold	$ 7,508

Note 4 - Property and Equipment - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment, Net	$ 25,034	$ 25,171
Manufacturing Equipment [Member]
Property, Plant and Equipment, Net	3,420	3,492
Winnebago Building [Member]
Property, Plant and Equipment, Net	19,275	19,406
Property, Plant and Equipment, Other Types [Member]
Property, Plant and Equipment, Net	$ 2,339	$ 2,273

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2020	May 11, 2020
Document Information [Line Items]
Entity Registrant Name	XBiotech Inc.
Entity Central Index Key	0001626878
Trading Symbol	xbit
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		28,852,927
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock, no par value

Note 8 - Income Taxes (Details Textual) - USD ($) $ in Thousands		3 Months Ended
	Jan. 01, 2020	Mar. 31, 2020	Mar. 31, 2019
Income Tax Expense (Benefit), Total		$ (352)	$ 0
Revenue from Contract with Customer, Including Assessed Tax		$ 12,681	$ 0
Effective Income Tax Rate Reconciliation, Percent, Total		12.50%
Domestic Tax Authority [Member] \| Canada Revenue Agency [Member]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	27.00%

Note 6 - Common Stock Options (Details Textual) $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($)
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 13.6
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 240 days
The Plan [Member] \| Any One Person [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum	5.00%
The Plan [Member] \| Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities
Net loss	$ (14)	$ (5,864)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	558	602
Share-based compensation expense	3,456	570
Account receivable	(9,681)
Deferred cost of goods sold	(1,703)
Income tax receivable	(3,793)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	489	230
Accounts payable	3,470	99
Accrued expenses	(2,815)	(311)
Deferred revenue	(3,000)
Deferred rent		(3)
Tax payable	(47,640)
Net cash used in operating activities	(60,673)	(4,677)
Investing activities
Purchase of property and equipment	(389)	(6)
Net cash used in investing activities	(389)	(6)
Financing activities
Share repurchases of common stock and warrants, net	(420,000)	541
Issuance of common stock under stock option plan	7,918	200
Net cash provided by (used in) financing activities	(412,082)	741
Effect of foreign exchange rate on cash and cash equivalents	90	138
Net change in cash and cash equivalents	(473,054)	(3,804)
Cash and cash equivalents, beginning of period	714,594	15,823
Cash and cash equivalents, end of period	241,540	12,019
Supplemental Information:
Accrued purchases of property and equipment	32	109
Subscription receivable		$ 102

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, no par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, shares authorized	Unlimited	Unlimited
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares outstanding (in shares)	28,852,927	41,519,633

Note 6 - Common Stock Options - Changes in Common Stock Options Issued (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Options outstanding (in shares)	6,965,730
Granted (in shares)	50,500
Exercised (in shares)	(1,333,294)	(771,000)
Forfeitures (in shares)	(12,167)
Options outstanding (in shares)	5,670,769	6,965,730
Minimum [Member]
Options outstanding, exercise price (in dollars per share)	$ 2.71
Granted, exercise price (in dollars per share)	8.89
Exercised, exercise price (in dollars per share)	2.94
Forfeitures, exercise price (in dollars per share)	4.95
Options outstanding, exercise price (in dollars per share)	2.71	$ 2.71
Maximum [Member]
Options outstanding, exercise price (in dollars per share)	21.99
Granted, exercise price (in dollars per share)	21.80
Exercised, exercise price (in dollars per share)	19.09
Forfeitures, exercise price (in dollars per share)	10.36
Options outstanding, exercise price (in dollars per share)	21.99	21.99
Weighted Average [Member]
Options outstanding, exercise price (in dollars per share)	6.09
Granted, exercise price (in dollars per share)	15.40
Exercised, exercise price (in dollars per share)	5.94
Forfeitures, exercise price (in dollars per share)	8.13
Options outstanding, exercise price (in dollars per share)	$ 6.17	$ 6.09

Note 5 - Common Stock (Details Textual) - USD ($)		1 Months Ended	3 Months Ended	12 Months Ended
Note 5 - Common Stock (Details Textual) - USD ($)	Feb. 19, 2020	Jun. 30, 2019	Mar. 31, 2020	Dec. 31, 2019	Jan. 04, 2020
Common Stock, No Par Value (in dollars per share)			$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)			1,333,294	771,000
Proceeds from Issuance of Common Stock			$ 7,900,000	$ 3,800,000
Stock Repurchase Program, Authorized Amount					$ 420,000,000
Stock Repurchased During Period, Shares (in shares)	14,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01
Stock Repurchased During Period, Price Per Share (in dollars per share)	$ 30
Stock Repurchased During Period, Value	$ 420,000,000
Percentage of Outstanding Shares Repurchased	32.67%
Stock Issued During Period, Value, Tender Off Payback			(420,000,000)
Common Stock [Member]
Stock Repurchased During Period, Price Per Share (in dollars per share)	$ 6.66
Stock Issued During Period, Value, Tender Off Payback	$ 93,240,000
Retained Earnings [Member]
Stock Repurchased During Period, Price Per Share (in dollars per share)	$ 23.34
Stock Issued During Period, Value, Tender Off Payback	$ (326,760,000)		$ (326,760,000)
Minimum [Member]
Shares Issued, Price Per Share (in dollars per share)			$ 2.94	$ 2.50
Stock Repurchase Program, Purchase Price Per Share (in dollars per share)					$ 30
Maximum [Member]
Shares Issued, Price Per Share (in dollars per share)			$ 19.09	$ 15
Stock Repurchase Program, Purchase Price Per Share (in dollars per share)					$ 33
Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		4,800,000
Shares Issued, Price Per Share (in dollars per share)		$ 8.25
Proceeds from Issuance of Common Stock, Net		$ 37,500,000
Underwriter's Commission Attributable to Issuance of Common Stock		2,300,000
Other Related Fee Attributable to Issuance of Common Stock		$ 200,000

Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock Including Additional Paid in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018	35,900,000
Balance at Dec. 31, 2018	$ 279,353	$ (255)	$ (237,700)	$ 41,398
Net loss			(5,864)	(5,864)
Foreign currency translation adjustment		138		138
Issuance of common stock under stock option plan (in shares)	190,000
Issuance of common stock under stock option plan	$ 643			643
Share-based compensation expense	570			570
Stock subscription receivable	(102)			(102)
Collection of stock subscription receivable	$ 200			200
Balance (in shares) at Mar. 31, 2019	36,090,000
Balance at Mar. 31, 2019	$ 280,664	(117)	(243,564)	36,983
Balance (in shares) at Dec. 31, 2019	41,519
Balance at Dec. 31, 2019	$ 324,808	(106)	430,929	755,631
Net loss			(14)	(14)
Tender offer buyback (in shares)	(14,000)
Tender offer buyback	$ (93,240)		(326,760)	(420,000)
Foreign currency translation adjustment		90		90
Issuance of common stock under stock option plan (in shares)	1,334
Issuance of common stock under stock option plan	$ 7,918			7,918
Share-based compensation expense	$ 3,456			3,456
Balance (in shares) at Mar. 31, 2020	28,853
Balance at Mar. 31, 2020	$ 242,942	$ (16)	$ 104,155	$ 347,082

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 241,540	$ 714,594
Accounts receivable	9,681
Deferred cost of goods sold	1,703
Income tax receivable	3,793
Prepaid expenses and other current assets	1,179	1,669
Total current assets	257,896	716,263
Property and equipment, net	25,034	25,171
Escrow receivable	75,000	75,000
Deferred tax asset	443	443
Total assets	358,373	816,877
Current liabilities:
Accounts payable	5,649	2,149
Accrued expenses	1,371	4,180
Contract Liabilities		4,500
Deferred revenue	1,500
Income taxes payable	1,715	49,361
Total current liabilities	10,235	60,190
Long-term liabilities:
Deferred rent
Income tax payable - non-current	1,056	1,056
Total liabilities	11,291	61,246
Shareholders’ equity:
Preferred stock, no par value, unlimited shares authorized, no shares outstanding	0	0
Common stock, no par value, unlimited shares authorized, 28,852,927 and 41,519,633 shares outstanding at March 31, 2020 and December 31, 2019, respectively	242,942	324,808
Accumulated other comprehensive loss	(16)	(106)
Retained earnings	104,156	430,929
Total shareholders’ equity	347,082	755,631
Total liabilities and shareholders’ equity	$ 358,373	$ 816,877